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THE NOVEL REGULATION OF HISTONE MODIFICATION 
IN CANCER DEVELOPMENT 
Xian Zhang 
Advisory Professor: Hui-Kuan Lin, Ph.D 
 
Dynamic changes in histone acetylation by various physiological cues play 
important roles in gene transcription and cancer. However, the cellular 
signaling underlying this regulation is not well understood. Here, we show that, 
in a glucose dependent manner, E3 ubiquitin ligase NEDD4 ubiquitinates 
histone H3 on previously unstudied lysine (K) 23/36/37 residues, which 
specifically recruits histone acetyltransferase (HAT) GCN5 for subsequent H3 
acetylation. Genome-wide analysis of chromatin immunoprecipitation followed 
by sequencing (ChIP-seq) data sets reveals that NEDD4 regulates glucose-
induced H3K9 acetylation at transcription starting site (TSS) and enhancer 
regions. Integrative analysis of ChIP-seq and microarray data sets also reveals 
a consistent role of H3 ubiquitination in transcription activation and H3 K9 
acetylation in response to glucose. Functionally, we showed that NEDD4-
mediated H3 ubiquitination is critical for tumorigenesis and that IL1A, IL1B 
and GCLM are important target genes to elicit the function of glucose-induced 
H3 ubiquitination in tumor sphere formation. Together, our study provides a 
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new model for glucose-induced transcriptome reprograming and epigenetic 
regulation in cancer through inducing NEDD4-dependent H3 ubiquitination. 
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1.1 Chromatin dynamics 
1.1.1 Chromatin structures	
The term ‘phenotype’ in biology is used to describe an observable characteristics 
or traits of an organism. Advances in technology leads to the observation of many 
phenotypes beyond our bare eyes, including phenotypes that exists at molecular or atomic 
level. Generally, phenotypes of an organism are the reflection of the interaction between 
genotypes and environmental factors. Genotypes refers to the complete set of genes in an 
organism. Genes are coded and carried by DNA double helix, which is a cellular 
macromolecule that is composed of deoxyribonucleotide acids. In eukaryote, the number 
and size of genes are so large that the DNA molecule carries it becomes extremely long, 
which is many orders of magnitude longer than the diameter of the nucleus (1). To fit 
such an long string into the relative small size of the round shaped nucleus, eukaryotic 
genomes are packed into dense structures, known as chromatin (2, 3). The basic structure 
units of chromatin are the nucleosomes, which are formed by wrapping approximately 
every 147 base pairs of DNA double strand around a protein complex.  The complex is 
composed of of eight core histone proteins, which are two copies of each histone H3, H4, 
H2A and H2B (4). The tandem repeat of nucleosome structures are connected by linker 
DNA, which is also called beads-on-a-string or 10nm fibre, is the euchromatin region of 
chromatin(5). With linker histone H1, multiple nucleosomes on the ‘string’ in some part 
of the chromatin are further packaged into 30nm fibers structures to form heterochromatin 
region of chromatin(5). During mitosis, 30nm fiber structure further packed into higher 
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level of structure is called metaphase chromosome(6). Thus, the changes in structure of 
chromatin are closely related to their biological function and will be discussed later.  
 
1.1.2 Histone variants 
There are five kinds of histone protein, which are H2A, H2B, H3, H4 and H1 as described 
above (4). Generally, DNA binds to core histone complex non-specifically (5). One of 
the notable characteristics of histone proteins is the large numbers and distinctive 
functions of their variants (7). Histone variants usually differ from their respective 
canonical ones from several amino acids or the addition of a large domain (7). Histone 
variants can be classified into replicative and replacement types according to their spatial 
and temporal involvement in the nucleosome structure (8). Replicative variants are 
transcribed in high amounts from tandemly arranged genes (different genes for the same 
protein) during S phase to ensure the replication of chromosome (9). Replacement 
histones are synthesized throughout the cell cycle and can be integrated into chromosome 
in a replication-independent manner (10). Each histone variant has a unique feature in 
sequence and thus enables it to interact with specific chromatin factors or DNA structures 
involved in various biological processes. For example, the incorporation or eviction of 
histone H3.3 by the histone chaperone, HIRA, occurs during cycle and is involved in the 
regulation of transcription, while H3.1 and H3.2 are only incorporated during replication 
(11, 12). Some of the histone variants are tissue specific or functional specific. CENPA, 
a large variant of H3 conveys special functions on the centromere, H3T is only expressed 
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in testes or sperm and H2AX is critical for the DNA damage response and DNA repair 
process (13-15).  
 
1.1.3 Chromatin remodelers 
As I have mentioned previously, environmental factors can also contribute to the 
changes of phenotypes.  Mutations in gene sequence, that can be induced by mutagens, 
may result in the changes of amino acid sequence and the structure of target protein, 
leading to the alteration in phenotypes. More frequently, a relative milder environmental 
factor may affect the organism at the epigenetic level, including stable changes in DNA 
methylation or histone modifications (16). Epigenetic changes often result in the 
reprograming of gene expression patterns, which are also closely linked to biological 
characteristics (16). In eukaryotes, genes are first transcribed to RNA, the process of 
which involves the binding of transcription machinery to the DNA double strand, 
indicating that an open status of DNA double strand is required for the transcription 
machinery to work (17). Hence, the basal status of eukaryotic genome is transcription 
suppressive as DNA is packaged to chromatin. To activate gene transcription, chromatin 
regions containing target genes have to be locally opened up for the access of transcription 
machinery. In various model organisms, it has been found that the chromatin structure is 
dynamic, including the events of opening up of chromatin for active transcription and 
closing off of chromatin for transcription repression.  These processes are achieved by a 
number of chromatin remodeling proteins, which often form larger complexes containing 
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functional specialized subunits (18, 19). Based on the functional definition, all chromatin 
remodelers share some basic properties, including the capability to bind to nucleosome, 
a DNA-dependent ATPase domain for trans-locating DNA from histone contact (DNA 
translocase), and the regulatory domains interacting with chromatin-associated factors 
and controlling the DNA translocase activity (20). Chromatin remodeler complexes are 
able to repositioning, ejecting, unwrapping, exchanging histone from nucleosome 
structures (20). Thereby, through regulating the direct accessibility of RNA polymerase 
II at specific chromatin sites, chromatin remodeler complexes could promote or inhibit 
transcription activity at multiple stages including transcription initiation, elongation and 
termination. Moreover, chromatin remodeler complexes also actively participate in other 
biological processes which require the access to DNA double strand within chromatin 
structure, including DNA replication, DNA repair and DNA recombination (21, 22). In 
human, the chromatin remodelers complexes are divided into four conserved families, 
namely SWI/SNF ISWI, CHD, INO80 family remodelers (Table 1). Each of them is 
composed of different ATPases and non-catalytic homologous subunits, which convey 
chromatin locus specificity and functional specialization (17).  
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SWI/SNF Complex BAF PBAF 
 ATPase hBRM/BRG1 BRG1 
 Non-catalytic subunits BAF250/hOSA1 BAF180 
    BAF200 
   BAF155, BAF170 
   BAF60a, b, c 
   hSNF5/BAF47/INI1 
   BAF57 
   BAF53a, b 
    b-actin 
ISWI Complex NURF CHRAC ACF 
 ATPase SNF2L SNF2H 
 Non-catalytic subunits BPTF hACF1/WCRF180 
   bAp46, 48 hCHRAC17   
      hCHRAC15   
CHD Complex CHD1 NuRD 
 ATPase CHD1 CHD3, CHD4 
 Non-catalytic subunits  MBD3 
    MTA1, 2, 3 
    HDAC1, 2 
    RbAp46, 48 
      p66a, b 
INO80 Complex INO80 SRCAP TRRAP/Tip60 
 ATPase hIno80 SRCAP p400 
 Non-catalytic subunits RUVBL1, 2/Tip49a, b 
   BAF53a 
   Arp5, 8 Arp6 Actin 
   hles2, 6 GAS41 
    DMAP1 
    YL-1 
    H2AZ, H2B Brd8/TRC/p120 
    ZnF-HIT1 TRRAP/Tip60 
      Tip60 
      MRG15 
      MRGX 
      FLJ11730 
      MRGBP 
      EPC1 
        ING3 
 
Table 1 The classification of chromatin remodelers in human (17). 
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1.1.4 Histone chaperones. 
Another group of critical factors in chromatin dynamics is the histone chaperones. 
They all bind histones and are broadly involved in histone transport, storage, nucleosome 
assembly and disassembly (23). Histone chaperones can be classified based on their 
binding substrates.  Most of the histone chaperones specifically bind to H2A-H2B or H3-
H4 oligomers, but a few of them recognize free histones, distinguishing the canonical 
ones and their variants (Table 2). Unlike the ATP dependent remodelers, histone 
chaperones utilize the spontaneous movement of the DNA around the dyad axis of 
nucleosome to destabilize the nucleosome, the process of which is slower than chromatin 
remodeling (20). Histone chaperones can also facilitate the histone exchange or regulate 
transcriptional activity by aiding the histone post translational modification (PTM) 
process at the desired locus. For instance, Rtt109-mediated H3K56 acetylation in the 
yeast is important for transcription initiation and elongation, but Rtt109 alone is not able 
to acetylate H3 within a nucleosome. Histone chaperone Asf1 mediated dissemble of 
nucleosome is required for Rtt109 to access H3 for acetylation (24). Similarly, histone 
methyltransferase Set2 also requires histone chaperone Spt6 for histone access and 
effective methylation (25). Thereby, histone chaperone mediated regulation of histone 
PTMs in turn alters the chromatin structures for transcription or other biological processes 
by its intrinsic chemical properties or by recruiting specific chromatin remodelers (20). 
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Histone Chaperone Histone bound Modulated event 
HIRA H3.3 H4S47 phosphorylation by PAK2 
NAP1 H2A-H2B, H2A.Z-H2B RSC remodeling 
FACT H2A-H2B H2BK120 ubiquitination by Rad6, H3K36 methylation by Set2 
ANP32E H2A.Z-H2B Unknown 
	
Table 2 Substrate and function of histone chaperones in human (20).  
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1.2 Histone modification and its biological function 
1.2.1 Histone acetylation 
The regulation or specialization of chromatin remodelers or histone chaperones at 
targeted chromatin locus or biological processes are largely achieved by histone 
modification, which is the covalent PTM on the histone proteins. For example, histone 
chaperones are required for histone modification at normally inaccessible sites, in turn, 
specific histone modification also facilitates or inhibits the histone exchange by recruiting 
or repelling chromatin remodelers or histone chaperones. For example, the binding of 
histone chaperone HIRA and its specific histone substrate H3.3 is facilitated by PAK2-
dependent H4 S47 phosphorylation, which disfavors its interaction with CAF1 (26). 
Rtt109 mediated H3 K56 acetylation facilitates histone exchange and transcription 
initiation, but Set2-mediated H3K36 methylation restricts histone exchange and 
transcription (25, 27). Thus to study the histone PTMs is important in understanding the 
regulation of chromatin structure and transcription.  
Generally, histone proteins are heavily post-translationally modified by 
phosphorylation, acetylation, methylation, ubiquitination and etc., which exert various 
functions in regulating chromatin structure through various mechanisms (28, 29). Histone 
acetylation is one of the well-known histone modifications that are frequently decorated 
at K4, K9, K14, K18, K23, K27, K36 residues on histone H3 and K16 on H4 (30). Histone 
acetylation at multiple sites is important, but sometimes is redundant for opening 
chromatin and activation of gene transcription (31, 32). Histones acetylation at lysine 
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residues on the one hand neutralizes its positive charge, thereby reducing the affinity 
between histone and negatively charged DNA. On the other hand, it recruits specific 
chromatin remodeler complexes that recognize acetylated lysine residue on histone 
proteins (33). The recognition requires specialized protein domains, including bromo 
domain and tandem PHD domain, which are shared features in some chromatin 
remodelers (34, 35). Histone acetylation, in essence, is an outcome of transferring an 
acetyl group from acetyl-CoA to the lysine residues on histone protein by specific 
enzymes known as histone acetyltransferases (HATs) that are often resides in larger 
chromatin remodeling complexes. Distinct families of HATs, including GNATs, MYST 
HATs and others, have been independently discovered and are responsible for histone 
acetylation (36, 37). It is generally believed that a HAT could target multiple lysine 
residues on histone and a lysine residue on histone could also be modified by multiple 
HATs (37). There might be some extend of redundancy in HAT functions, but emerging 
studies have indicated the substrate or lysine residue preference of HATs and the 
differential activity of HATs under curtain cellular contexts (38, 39). In the future study, 
a related question would be whether there is a preference in the usage of HAT under 
curtain physiological cue and, if yes, what would be the underlining mechanism to convey 
the specificity.  
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1.2.2 Histone methylations.  
Unlike acetylation that only occurs on lysine, histone methylation could be 
conjugated on arginine, lysine and histidine (40). A single lysine residue could be mono-
methylated, dimethylated or trimethylated on their ε-amine group. Lysine methylation on 
H3K4, H3K9, H3K27, H3K36, H3K79 and H4K20 are relatively well studied in the 
chromatin biology field, however, arginine methylation on H3-H4 and many other 
methylation events on H2A-H2B have also been identified by recent quantitative mass 
spectrometry analysis and their functions remain to be determined (41, 42). Histone 
methylation is catalyzed by histone methyltransferases, which are composed of three 
families including SET domain containing proteins and DOT1-like proteins for lysine 
methylation and protein arginine N-methyl-transferase family for the arginine 
methylation (41). Traditionally, it is believed that histone methylations are relative stable 
modifications and their turn over rates are much slower than other histone modifications 
until the discovery of histone demethylases, which actively and site specifically remove 
histone methylation. There are two families of demethylases, including amine oxidases 
and jumonji C domain containing iron dependent dioxygenases for lysine demethylation 
(43, 44). Arginine demethylases remain to be discovered, although monomethyl arginine 
can be converted to citrulline by PADI4 (45). The precise recruitment of 
methyltransferases and demethylases to their target histones is an important area of study. 
Consensus DNA sequences have been identified as binding sites for several histone 
remodeling complexes containing methyltransferase and demethylase. For example, 
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polycomb group response elements directly recruit polycomb repressive complex 2 
(PRC2), which could catalyze H3 K27 trimethylation, though DNA binding transcription 
factors that recognize consensus DNA elements (46, 47). Long non-coding RNAs 
(LncRNA) are known to interact with DNA sequences with high sequence specificity, 
and are reported to be adaptors in the targeted methylation and demethylation process. 
LncRNAs have been shown to interact with PRC2 complex and H3K4 methyltransferase 
complex member WD repeat domain 5 (WDR5) (48, 49). With the identification of large 
number of lncRNAs in human, it is possible that they may mediate a great many of gene 
specific regulations and may be the major mechanism for gene specific interaction 
between DNA and chromatin factors. Histone methylations are recognized by proteins 
with methyl-binding domains, including PHD finger, WD40 repeat, CW domain, PWWP 
domain, ankyrin repeat and royal superfamily, which further includes chromo domain, 
double chromo domain, chromobarrel, tudor domain, double or tandem tudor domain and 
MBT repeats (42). Since methylation generally adds a positive charge and hydrophobicity 
to lysine and arginine, any proteins with hydrophobic properties, aromatic cages and 
composite pockets could potentially bind to histone methylations (42). Unlike histone 
acetylation, it is more clear that the location and degree of methylation are both critical 
for its biological functions. For example, H3 K4 trimethylation is generally a marker for 
transcriptional activation, while H3 K27 trimethylation is a repressive marker for 
chromatin (50, 51). H3 K79 dimethylation is crucial in cell cycle regulation, but H3 K79 
trimethylation is associated with the Wnt signaling pathway (52, 53). Interestingly, the 
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transcriptional activation marker H3K4 methylation, when binding to PHD domain 
containing co-repressor protein inhibitor of growth family member 2 (ING2), are 
associated with the repression of transcription (54).  Hence, to study the dynamic changes 
of histone methylation is important to understand epigenetic regulations in various 
cellular processes.  
 
1.2.4 Quantitative mass spectrometry and novel histone modifications.  
Studies of histone modification often involve the generation of site specific 
antibodies. However, except for the issue of antibody specificity, antigen occlusion is a 
severe issue for such a densely post translationally modified protein, like histone proteins. 
Quantitative mass spectrometry (MS) is developed for PTM study and could 
simultaneously identify large numbers of PTMs on a large number of proteins in a much 
less biased way for biological samples under various conditions (55). Basically, total 
proteins were extracted and solubilized. Trypsin protease is commonly used for 
generating MS “friendly” peptides, while other proteases might also be used alone or in 
combination if the digestion pattern of trypsin is not ideal in some biological samples. 
Unlike traditional MS, quantitative PTM MS usually requires an additional enrichment 
step, including the usage of chemical, antibody or protein affinity to enrich the specific 
modification of interest. The best example would be the development of an antibody that 
specifically recognizes di-Glycine linked lysine, which is the left over modification of  
ubiquitinated lysine after trypsin digestion (56). Using this antibody, cellular 
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ubiquitinated proteins can be enriched before MS identification, which is used to be very 
inefficient in identification of protein ubiquitination. Enriched peptides were then sent for 
standard shot gun MS and subsequent computational analysis with optimized parameters 
for identifications of specific PTMs. Particularly, to generate data with high reliability, it 
is important to estimate the sufficient hits to cover the complete model peptides catalogs 
in the MS experiments.  However, it is very difficult to generate the complete model 
catalogs for total cellular PTMs with current computational resources due to the great 
number of possible PTMs and PTM combinations on the same protein. Also, modern MS 
generated far less than sufficient hits for such a big model set of PTMs (57). Despite the 
robustness in study the global PTMs, it is relatively capable of discovering and 
quantifying the PTMs on limited protein targets, like histone proteins. Now, quantitative 
MS has broadened our view in histone modifications, since many novel and exotic PTMs 
were found, such as crotonylation, 2-hydroxysobutyrylation, malonylation, succinylation 
and etc. (58) Functional characterization of such modifications would be important follow 
up works for PTM MS and may create a new paradigm for chromatin biology.  
 
1.3 Regulation of histone modification  
1.3.1 Metabolism dependent regulation of histone modification.  
Eukaryotic cells adapt to changes in its environment to survive and proliferate. As 
mentioned earlier, the most important adaptation is achieved by a precise reprogramming 
of gene expression to fine-tune the cellular functions in face of environmental conditions. 
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The dynamics of histone modification are critically responsible for the altered gene 
transcription. With regard to stress-induced changes in histone modification, there are 
basically two aspects. One is the stress sensing machinery in the cells to transduce 
environmental changes to cellular signaling pathways, the other one is the activated 
signaling cascades that eventually activate the histone modification enzymes to regulate 
gene transcription (59). Alternatively, environmental changes like metabolism related 
changes have been shown to regulate histone modification directly, as many metabolic 
intermediates are co-factors or substrates for the enzymatic reaction of histone 
modifications (60). Glucose deprivation, which causes a rapid decrease in cellular energy, 
is proposed to affect histone acetylation through depletion of cellular acetyl-CoA and/or 
elevating the NAD+/NADH ratio, which inhibits HATs but activates histone deacetylases 
(HDACs), such as Sirtuin (61).  
Another important histone modification affected by metabolism is the histone 
methylation. All histone methyltransferases use S-adenosyl-methionine (SAM) as a 
methyl donor for methylation and also produce S-adenosyl-homocycsteine (SAH), which 
is an inhibitor of SAM on a similar reaction order (62). Thus fluctuation of cellular levels 
of SAM/SAH may affect histone methylation. SAM is synthesized from methionine and 
ATP. SAH is converted to homocysteine, which can be either degraded or re-enter into 
the SAM cycle through re-methylation to methionine. These reactions are all essentially 
dependent on vitamins, especially folate, vitamin B6 and vitamin B12 (63). Thus, histone 
methylation could be affected by the input of other metabolic pathways to the SAM cycle, 
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cellular availability of vitamins and any factors that affect the enzymes in the SAM cycle. 
There are a growing number of evidences that support this idea. For example, inhibition 
of threonine to SAM decreased the SAM/SAH ratio, H3 K4 methylation and restricted 
embryonic stem cell growth and differentiation (64). Histone demethylase LSD family is 
FAD-dependent and JmjC family is α-ketoglutarate dependent. These two metabolites 
are both closely linked to mitochondria oxidative metabolism and are component of TCA 
cycle (65). Alteration in the cellular level of FAD/FADH2 or a-KG affects histone 
methylation level, and gene transcription (66). Mutations in metabolic enzymes have been 
characterized in human cancer and affect histone methylation and affect cancer growth 
and metastasis (67). As metabolic intermediates globally affect enzymatic conjugation or 
removal of histone modifications, this mechanism alone is unlikely to achieve gene 
specific regulation for metabolic adaptation to a new environment. Hence, a more 
sophisticated cellular signaling network accounting for it remains to be characterized for 
the transcriptomic reprograming upon metabolic changes.  
 
1.3.2 Studying the dynamics of histone modification.  
With the development of next generation sequencing technology, chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) method has been widely used 
to obtain the genome wide DNA binding site information of any protein of interest (68). 
To study how a specific transcription factor or histone modification linked to biological 
functions or phenotypes requires the identification of downstream effector genes. ChIP-
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seq is mainly used to understand such regulatory mechanism both globally and gene 
specifically. ChIP-seq is performed by capturing protein binding DNA by traditional 
ChIP method first, followed by adding oligonucleotide adaptors to those small DNA 
fragments for massive parallel sequencing and computational analysis. Cancer cells or 
stem cells are known to be heterogenetic, thus the chromatin and transcription status are 
distinct in each cells. By utilizing the microfluidic droplet barcoding technology, DNA 
fragments from each cells were separated in each droplet and barcoded respectively for 
next generation sequencing (69). This technology enabled us to understand the 
heterogeneity of human cancers or stem cells and to identify small subpopulations with 
unique feature and functional importance.  
Classical methods and sequencing technology have built the foundation of 
chromatin biology. However, the spatial and temporal resolution of such ‘snapshot’ 
methods are low to monitor the dynamic and rapid process of transcription initiation, 
elongation and termination. Recent advances in fluorescence microscopy and transfection 
of single chain antibody facilitate the development of technology that can visualize 
chromatin or transcription dynamics at a single site level (70). Single transcription factor 
or histone modification tracking within a single cell enabled us to ‘see’ how transcription 
factors are recruited by histone modification and assembled at their target sites. Super-
resolution microscopy based technology enabled us to map the chromatin structures at a 
single nucleosome resolution (71). New technologies have helped us to either confirm or 
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challenge existing concepts in the chromatin biology field and may put great insights into 
the future study.  
 
1.4 Cancer stem cell theory 
1.4.1 The basic concept of cancer stem cells 
  Current concepts suggest that cancers are originated from abnormal genetic or 
epigenetic alterations (72). A small portion of cancer cells, displaying the capability of 
self-renew and generation of large number of more differentiated form of cancer cells, 
are called cancer stem cells (CSCs), which are likely responsible for tumor initiation, 
metastasis, relapse and drug resistance(73, 74). Cancer stem cell is initially a hypothesis 
proposed to explain the heterogeneity of cancer cells (75). Until mid 1990s, a 
subpopulation of leukemia with stem cell like properties was discovered and named 
‘cancer stem cells’, mimicking the multipotency and self-renewal properties of adult stem 
cells (76). Later, cancer stem cell theory was extended to solid tumors and it has been 
identified in almost every cancer types today (77). According to the cancer stem cell 
hypothesis, cancer stem cell is capable of forming a new tumor in the immune 
compromised animal model, while differentiated cancer cells can not (78). However, 
inconsistent results showing that limited number of differentiated cancer cells can also 
form tumor in xenograft model have been observed (79, 80). Although this might be due 
to the inaccuracy of methodology and the fact that all cancer stem cells must be removed 
to eliminate cancer, development of other models may explain those observations and the 
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original cancer stem cell theory should be modified.  In fact, cancer stem cell is not the 
only theory to explain the cancer heterogeneity. Stochastic model and the model 
emphasizing the importance of the unique environment of a given cell have also been 
proposed (81). Their basic ideas are about that intrinsic genetic or epigenetic variations 
or extrinsic microenvironment differences within a group of cancer cells caused the 
heterogeneity, which is interchangeable upon changes of intrinsic or extrinsic factors (81). 
In the field of tumor initiation, there is increasing support for a non-mutually exclusive 
model that combines all above three models to explain the heterogeneity of cancer and 
explain the tumorigenicity of differentiated cancer at a given time (82). Although the 
cancer stem cell theory is under debate, the study of this interesting subpopulation of cells 
remains critical due to its possible drug resistance feature in cancer therapy (83). Cancer 
stem cells in many types of cancers are known to be resistant to chemotherapy and 
radiation therapy. Treating cancer without taking cancer stem cells into account would 
enrich cancer stem cells and exacerbating the malignancy of many cancers (79). Thus the 
identification and study the drug resistance mechanism of cancer stem cells become an 
urgent task in the cancer stem cell field. 
 
1.4.2  Cancer stem cell markers. 
 To identify and study cancer stem cells, the methods include the isolation of 
specific surface markers or the use of selective culture conditions that prefer the 
clonogenicity of cancer stem cells, including in vitro sphere forming assay, in vivo limited 
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dilution of xenograft engraftment assay, renal graft assay and etc (84). Live imaging and 
in vivo lineage tracking are also important methodology to monitor the self-renewal and 
multipotency of cancer stem cells (84). Various biomarkers have been identified for many 
cancer types as listed in the table 3. Cancer stem cell markers can be classified into several 
categories. The most common one is the cell surface marker category, which is selected 
by contrasting the cell surface markers of cancer cells grow under normal and cancer stem 
cell enrichment environment. Surface markers facilitate the researchers to use flow 
cytometry to analysis the population of cancer stem cells or use fluorescence activated 
cell sorting (FACS) or magnetic activated cell sorting (MACS) to isolate putative cancer 
stem cells for the functional study (84). The next category is drug resistance markers, 
especially include many chemo drug efflux transporters at cell surface to convey the drug 
resistant feature of cancer stem cells. However, controversial data showing that drug 
resistant markers does not enrich the tumorigenicity of cancer cells in xenograft were 
observed in some cancer types (83, 85), suggesting that using markers for drug resistance 
alone may not be ideal to distinguish cancer stem cells. Another important category of 
markers is the markers for pluripotency. Embryonic stem cell pluripotent factors, like 
Oct4, Sox2 and Nanog are important for cancer stem cells, as the embryonic stem cell 
gene expression signature was also observed for cancer stem cells in many cancer types 
(86). However, the presence of multiple splicing variants of those pluripotent factors 
complicated the marker detection, since most of the variants are inactive. Thus, simply 
checking transcription activity of pluripotent genes by GFP reporter or protein expression 
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level by immunofluorescence staining is not sufficient and it is risky to link such 
observations to the the evidence of cancer stem cells. Thus using multiple markers and 
functional analysis methods are crucial in studying the cancer stem cells. However, there 
are still some limitations of even combining those methods. First, cancer stem cell traits 
(markers or functions) may be context specific and depending on the specific tumor 
microenvironment, which is different from assay conditions. Moreover, it is not clear 
whether cancer stem cells or non-stem cancer cells can be converted mutually. This 
plasticity in phenotypes raises serious questions in the validity of marker isolated cancer 
stem cells in this field of study (82).  
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Breast Lung Melanoma Ovarian Pancreatic Prostate 
ALDH1 ABCG2 ABCB5 CD24 ABCG2 ALDH1 
BMI-1 ALDH1 ALDH1 CD44 ALDH1 BMI-1 
CD24 CD90 CD20 CD117 BMI-1 CD44 
CD44 CD117 CD133 CD133 CD24 CD151 
CD133 EpCAM Nestin Ovastacin CD44 CD166 
CXCR4  NGF R  CD133 Integrin a1, b1 
DLL4    c-Met Integrin a6 
GLI    CXCR4 Trop2 
Her2    PON1  
IL-1a      
Integrin a6      
PTEN           
 
Table 3 List of cancer stem cell markers in various solid tumors (87).  
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Accumulating evidences suggested that cancer stem cell markers are not mere 
cancer stem cell defining molecules.  CD44+ is widely used cancer stem cell markers in 
various cancer types, pointing the important role of CD44 in tumors. CD44 is a 
transmembrane glycoprotein composed of a conserved extracellular hyaluronan (HA)-
binding domain, variably spliced regions, transmembrane sequences and intracellular 
cytoskeletal-signaling domains (88). One of the interesting areas of research in cancer 
stem cells is to study interaction of CD44 with the extracellular matrix HA, which 
promotes adhesion, migration and invasion of cancer cells (89). Other studies also found 
that HA-bound CD44 interacted with and promotes the receptor downstream kinase 
signaling of human epidermal growth factor receptor 2 (HER) (90). HA-bound CD44 
activates p300-dependent acetylation of beta-catenin and NF-κB (91). HA-CD44 
complex also activates Nanog, which subsequently promotes stem cell factor SOX2 and 
drug efflux transporter MDR1 (92). Cancer stem cell marker CD133 is also a 
transmembrane glycoprotein, but its biological role is not yet well defined as CD44. 
However,  the property of the CD133+ cancer cells has been studied and associated to 
many stemness factors, drug resistance transporters, receptor tyrosine kinase signaling 
and HIF hypoxia related signaling (93).  
Aldehyde dehydrogenase (ALDH) activity is another marker widely used in 
variety of cancer types. Hematopoietic stem cells display high level of ALDH activity, 
mainly through high expression of ALDH1 gene (94). This concept was then adopted in 
the cancer stem cell field for many cancer types. ALDH converts retinol to retinoic acid, 
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which is important for stem cell differentiation (95). It has also been suggested that 
ALDH could mediate the oxidation of many toxic aldehydes, in turn promote the 
maintenance of cancer stem cells and possibly drug resistance (95). Similar to the role of 
cancer stem cell markers as a cancer stem cell defining molecules, there were 
controversial data reported for the function of those cancer stem cell markers in different 
cancers types (96), suggesting that the functions of those cancer stem cell markers are 
also context dependent.  
 
1.4.3 Signaling pathways involved in the cancer stem cells. 
Cancer stem cells have been shown to harbor altered cellular signaling pathways, 
especially the pathways that are involved in stem cell self-renew, development and 
differentiation, including Wnt/β-catenin, hedgehog, BMP, TGF-β and notch signaling 
(97-99). Wnt signaling pathway has been suggested in the maintenance of both normal 
stem cells and cancer cells. Wnt binds receptor Frizzled and activates Dvl, in turn 
inhibited Axin/APC/GSK3-beta complex mediated beta-catenin turn over and promote 
beta-catenin downstream target transcription (100). In the case of cancer stem cells, 
inhibition of Wnt signaling results in the increased chemo-sensitivity for the chemo 
resistant population of cancer cells and reduced expression of stemness factor OCT4 
(101), suggesting a critical role for Wnt in cancer stem cell functions. Notch signaling 
pathway determines cell fate probably through its four different Notch isoforms, the 
function of which are non-overlapping and/or opposing on differentiation and 
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development (102). This fact explains the observation that Notch1/2 in SCLC is tumor 
suppressive, but Notch3 is up-regulated in NSCLC (103). ALDH+ population of NSCLC 
has been shown to be dependent on Notch activity for clonogenicity (104), indicating a 
role of Notch in cancer stem cell function. The hedgehog pathway is a extensively studied 
area in developmental and stem cell biology, which regulates stem cell maintenance, 
proliferation and differentiation. Hedgehog binds to receptor patched-1 and releases 
smoothened protein from the membrane. Activated smoothened further antagonizes Gli 
and its downstream target. Deregulated hedgehog pathway results in tumor proliferation 
and metastasis (105). It is also reported that Hedgehog pathway promotes mammosphere 
formation and cancer initiation through cancer stem cell factor BMI, and pharmacological 
inhibition of Hedgehog pathway reduced CD133 or CD44 cell population (106), 
indicating its involvement in the maintenance of cancer stem cells. Together, studying 
signaling pathways related to cancer stem cells extended our view of cancer development 
and may facilitate the drug design for resistant cancer cells.  
 
1.5 Protein ubiquitination and its role in signaling  
1.5.1 Basic concepts of ubiquitination 
Ubiquitination is a one of the well-studied post-translational modifications that is 
critically involved in many cellular processes (107). Basically it is a reaction of covalent 
attachment of the ubiquitin protein to the lysine residues on the substrate proteins. 
Ubiquitin is a small protein found in eukaryotic and there are four fusion genes in human 
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that can produce the precursor of ubiquitin. The ubiquitination process is accomplished 
by a cascade of reactions that involves three enzymes, namely E1 ubiquitin-activating 
enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligase (107). Ubiquitin is 
first activated by a ATP dependent two-step reaction by E1. Initially, E1 binds to ATP 
and catalyzes the acyl-adenylation of the C-terminus of ubiquitin. Adenylated C-terminus 
then forms a thioester bond with the cysteine sulfhydryl group on E1. E2 enzyme 
catalyzes a transesterification reaction, which transfers the ubiquitin from E1 to the active 
site cysteine of E2. At last step, E3 ligase catalyzes the formation of the isopeptide bond 
between a lysine residue of the substrate protein and C-terminus of ubiquitin. Human 
cells possess hundreds of E3 ligases to catalyze the ubiquitination of various substrates 
(107). E3 ligases generally determine the substrate specificity of the ubiquitination. 
HECT domain and RING domain E3 ligases are two basic categories (108). HECT 
domain E3 ligase forms a transient binding with ubiquitin, while RING domain E3 ligases 
directly transfer ubiquitin from E2 to substrate. Other E3 ligases include Anaphase-
promoting complex (APC) and Skp, Cullin, F-box containing complex (SCF), which are 
large E3 ligase complexes that recognize substrates and transfer ubiquitin through the 
cooperation of different subunits (109).  
Ubiquitination chain can range from mono, poly or even multi-mono, multi-poly 
ubiquitination, which decide the distinct fate of the substrate proteins (107). Mono 
ubiquitination can be involved in protein trafficking, endocytosis and viral budding. The 
situation for poly ubiquitination is more complicated. Depending on the linkage residue 
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between ubiquitin molecules within poly ubiquitination chain, it can form K6, K11, K27, 
K29, K33, K48, K63 and M1 linkage (107). K48 linked poly ubiquitination is the most 
well-studied one and its conjugation on protein marks the proteins for proteasomal 
degradation. K48 linked ubiquitination is recognized by the 26S proteasome and substrate 
proteins are rapidly degraded by proteases inside the proteasome, while ubiquitin chain 
is cleaved before this process and recycled for further usage. K63 linked ubiquitination 
does not trigger proteasomal degradation, but is involved in the various cellular processes 
including endocytosis, inflammation, kinase activation and DNA repair (107). K63 linked 
ubiquitination can be recognized by the ubiquitin binding domains, including UIM, UBA, 
UBC and etc., allowing that K63 linked ubiquitination to serve as a molecular scaffold to 
transduce and amply the cellular signaling (110). Little is know about other types of 
linkage, since the observations and functional studies of those linkages are just emerging 
and their involvement in cellular processes is largely unclear.  
 
1.5.2 Nedd4 family E3 ligase and their function.   
As mentioned above, E3 ligases are mainly categorized into two groups, by either 
containing a zinc-binding RING finger E2-binding adaptor domain or a Homologous to 
the E6-AP Carboxyl Terminus (HECT) catalytic domain.  Nedd4 family E3 ligases 
belong to the HECT domain class of E3 ligases. Nedd4 is initially found in a screen for 
genes developmentally down regulated in the early embryonic mouse central nervous 
system (111). Other E3 ligases with similar structures, which are now Nedd4 family 
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members are subsequently found and characterized. They are Nedd4L, ITCH, SMURF1, 
SMURF2, WWP1, WWP2, NEDL1 and NEDL2 in human (111). Structurally, they all 
contain a HECT domain, a C2 domain and several WW domains on the N terminal for 
substrate recognition (111). However, shared molecular structure does not result in a 
redundant biological function, since individual knockout of Nedd4 family gene often 
exhibits strong phenotypes or even causes embryonic lethality (111). Consistent with the 
general concept of E3 ligases, this observation suggests that they may have different 
substrate specificity.  
Nedd4 activity is regulated by auto-inhibition, where its C2 domain binds to its 
HECT domain to form an inhibitory structure (111). This inhibition can be disrupted by 
calcium, or phosphorylation of NEDD4 at specific tyrosine residues to activate the E3 
ligase activity (112, 113). The WW domains on Nedd4 is required to recognize PY motif 
(PPxY) on its substrate, while adaptor proteins NDFIP1 and NDFIP2 can assist the 
binding between Nedd4 and it substrates lacking PY motifs (114). The HECT domain on 
Nedd4 forms a thioester bond with ubiquitin before it is transferred from Nedd4 to its 
substrates. Nedd4 has been shown to ubiquitinate several ion channels and membrane 
transporters and receptors, which often leads to endocytosis and proteasomal degradation 
of its substrates (115). While the majority of Nedd4 substrates localizing in either 
cytoplasm or plasma membrane are identified, its nuclear substrate is less well-defined. 
In vivo, Nedd4 deficiency causes embryonic lethality and profound decrease in IGF-1 and 
insulin signaling (115-117). Deletion of Nedd4 also leads to a reduction in effector T-
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cells due to the impairment in the conversion of naïve T-Cells to activated T-Cells (118). 
Nedd4 is required for the neuronal development, the formation of dendrites in neuron and 
neuron muscular junctions and keeping the normal number of motor and axon neurons 
(119). Nedd4 has also been shown to poly-ubiquitinate tumor suppressor PTEN and drive 
proteosomal degradation of PTEN (120). However, in certain models, Nedd4 seems does 
not target PTEN for degradation (121). Although Nedd4 has been reported to be 
frequently overexpressed in many cancer types, its decrease is also associated with some 
cancers, where Nedd4 suppresses cancer through targeting N-Myc or c-Myc for 
degradation (115, 122). However, whether Nedd4 has a role in CSC regulation is not clear.  
  
1.5.3 Rationale and Hypothesis  
HATs often reside in larger protein complexes for the gene-specific recruitment 
and targeted histone acetylation(37). However, the mechanism underlying the recruitment 
of HATs for global histone acetylation is unclear. As depleting subunits recognizing 
known motifs or histone modifications in HAT complex did not affect global histone H3 
acetylation (123), we speculated that there are other previously unknown H3 
modifications, which may be involved in the global recruitment of HATs. By analyzing 
the published large-scale quantitative mass spectrometry data sets (124-126), we found 
that H3 proteins were ubiquitinated on multiple lysine (K) residues. Interestingly, this 
ubiquitination is also induced by glucose, suggesting that H3 ubiquitination may be a 
potential prerequisite for HAT recruitment and H3 acetylation upon glucose stimulation. 
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Since cancer stem cells represent a therapeutically challenging population of cancer cells, 
we also seek to examine whether this glucose induced H3 acetylation and its downstream 
target genes are involved in the regulation of cancer stem cells.  
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Chapter 2 Materials and Methods 
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2.1 Cell culture, glucose treatment, transfection, viral transduction and 
reagents.  
Hep3b, HEK293T, Du145 cell lines were purchased from ATCC and cultured in 
DME/F12 medium (GE Healthcare HyClone) in 10% Fetal bovine serum (FBS, Sigma 
Aldrich), Penicillin Streptomycin (Pen Strep) and L-glutamine. WT and Nedd4-/- MEFs 
cultured in DMEM medium containing 10% FBS were obtained from Dr. Xinjiang Wang. 
For the add-back of glucose procedure, 80% confluent cells were cultured in DMEM 
medium without glucose (Invitrogen) for 4 hours and resupplied with glucose (4.5g/L) 
for indicated times. 293T cells were transfected by standard calcium phosphate method. 
Other cell lines were transfected using Lipofectamine 3000 (Invitrogen) by the 
manufacturer’s protocol and if indicated, cultured in medium containing Hygromycin B 
(100 ug/mL) to establish stable cell lines. For lentiviral infection, 293T cells were co-
transfected with lentiviral plasmid (pLKO-puro), packing plasmid (deltaVPR8.9) and 
envelope plasmid (VSV-G). 2 days after transfection, medium containing virus particles 
were used to infect mammalian cell lines. All the infected cells were cultured in the 
medium containing 2μg/ml puromycin for 1 week before further analysis. Short 
interfering RNA (shRNA) for NEDD4, H3.3 and GCN5 were purchased from Sigma 
Aldrich. Flag-H3.3 plasmid and lentiviral Flag-H3.3 plasmid were obtained by inserting 
human H3.3 open reading frame into pCDNA3.1-hygro or pLKO-as3w-puro vectors 
respectively. All H3.3 mutation constructs (K4R, K9R, K14R, K18R, K23R, K27R, 
K36R, K37R, K36/37R, K23/36/37R, K56R, K64R, K79R, K115R and K122R) were 
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generated by site-directed mutagenic PCR according to the kit manual (Stratagene). His-
ubiquitin plasmid was previously described(127). HA-BMI-1 and HA-RNF2 were 
obtained from Dr. Shiaw-Yih Lin. HA-NEDD4 and HA-UHRF-1 plasmids were from 
Drs. Pier Paolo Pandolfi and Hung-Ying Kao, respectively. HA-CBL-A, HA-CBL-B and 
HA-CBL-C were received from Dr. Stanely Lipkowitz. Flag-HA-RNF8 was kindly 
provided by Dr. Junjie Chen. V5-NEDD4 WT, Y43/585F and Y43/585E mutant are from 
Dr. Daniela Rotin. Flag-NEDD4L, NEDL1 and NEDL2 are from Dr. Wesley Sundquist. 
Flag-WWP1 and WWP2 are from Dr. Wenyi Wei. The following antibodies were used 
in this study: anti-H3 (Abcam, ab12079), anti-H3 pan-ac (Active Motif, 39139), anti-H3 
K4ac (Active Motif, 39381), anti-H3 K9ac (Active Motif, 39917), anti-H3 K14ac (Active 
Motif, 39697), anti-H3 K18ac (Active Motif, 39755), anti-H3 K23ac (Active Motif, 
39131), anti-H3 K27ac (Active Motif, 39133), anti-H3 K36ac (Active Motif, 39379), 
anti-H3 K56ac (Active Motif, 61061), anti-H3 K4me3 (39915), anti-H3 K9me3 (Active 
Motif, 39765), anti-H3 K27me3 (Active Motif, 39155), anti-H3 K4me2, K9me2, 
K27me2, K36me2, K79me2 (Cell Signaling Technology, 9847), anti-H3s10p (Abcam, 
ab5176), anti-H3.3 (EMD Millipore, 09-838), anti-NEDD4 (Novus, NBP1-40112), anti-
GCN5 (Active Motif, 39975), anti-USP22 (Abcam, ab4812), anti-Flag (Sigma), anti-HA 
(Covance), anti-Actin (Sigma), anti-IL1α (Abcam, ab17281), anti-IL1β (Abcam, ab2105) 
and anti-IgG heavy chain HRP (Sigma Aldrich, a1949). The following recombinant 
proteins were used in this study: active NEDD4 (Millipore), histone octamer (EMD 
Millipore), E1 enzyme (Sigma Aldrich), UbcH4 (EMD Millipore), UbcH5a (EMD 
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Millipore), UbcH5b (EMD Millipore), UbcH5c (Boston Biochem), UbcH6 (EMD 
Millipore), UbcH7 (Boston Biochem), ubiquitin (Boston Biochem), GST-ubiquitin 
(Millipore), GCN5 (Novus), IL1β human (Sigma Aldrich). The following chemicals were 
used in this study:  N-acetyl-L-cysteine (NAC) (Sigma Alrich), N-Ethylmaleimide (NEM) 
(Calbiochem) and DCFDA (Invitrogen). 
 
2.2 In vivo ubiquitination assay.  
In vivo ubiquitination assay was performed as previously described(127). Briefly, 293T 
cells were transfected with his-Ubiquitin and other indicated plasmids for 36 hours and 
harvested by denaturing buffer (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 10 mM 
imidazole). Ni-NTA Agarose beads (QIAGEN) were incubated with cell lysates for 3.5 
h to pull-down his-Ubiquitin and washed beads were analyzed by Western blot.  
 
2.3 In vitro ubiquitination assay.  
3ug recombinant histone octamer and 5ug active form of NEDD4 were incubated with 
0.5 µg E1 activating enzyme, 1.5 µg Ubiquitin, 0.5 µg various E2 enzymes UBCH4, 
UBCH5a, UBCH5b, UBCH5c, UBCH6 or UBCH7 and 2.5 mM ATP in reaction buffer 
(1.5 mM MgCl2, 5 mM KCl, 1 mM DTT, 20 mM HEPES (pH7.4)) in a total 20ul reaction 
volume at 37°C for 3 hours. Ubiquitination on substrate was then detected by Western 
blot analysis.  
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2.4 Whole cell extracts for histone modification detection, cellular fractionation, 
chromatin fractionation and immunoprecipitation.  
Whole cell extracts were prepared by boiling the cell pellets in SDS sample buffers for 
10min. Cytosol and nucleus were purified using standard protocol. Briefly, cells were re-
suspended in hypertonic buffer (10mM Tris pH 7.6, 10mM MgCl2, 0.1% NP-40), then 
lysed using Dounce homogenizer and centrifuged at 1000g. Pellets containing nucleus 
were washed twice with hypertonic buffer. Supernatant containing cytosol was further 
cleared by centrifuging at 12000g. Chromatin fractionation was performed as 
described(128). Briefly, cells were first lysed with buffer A (50 mM Hepes, pH 7.9, 10 
mM KCl, 1.5 mM MgCl2, 0.34 M Sucrose, 10% Glycerol, 1 mM DTT, 0.1% Triton X-
100, NEM, protease inhibitor cocktail (Biotool) and phosphatase inhibitor cocktail 
(Biotool)) on ice for 30 min. After centrifuge at 1000g, pellets including the nucleus were 
further lysed with buffer B [3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, NEM, protease 
inhibitor cocktail (Biotool) and phosphatase inhibitor cocktail (Biotool)]. After centrifuge, 
pellets containing the chromatin were washed, and sonicated in SDS sample buffer for 
Western blot analysis. To immunoprecipitate proteins, cells were lysed and sonicated in 
RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate, 
1% NP-40, 1mM EDTA, protease inhibitor cocktail (Biotool), phosphatase inhibitor 
cocktail (Biotool) and NEM). Cell lysates were incubated at 4°C with antibody overnight 
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and agarose protein A/G beads for 3 hours, and then beads were washed with RIPA buffer 
for 5 times before eluting with SDS sample buffer. 
 
2.5 Endogenous ubiquitination assay.  
Briefly, cells were collected and boiled in SDS lysis buffer (2% SDS, 150 mM NaCl, 50 
mM Tris-HCl, pH 7.4, protease inhibitor cocktail) for 10 min. Lysate was sonicated and 
diluted 10 times with dilution buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 0.5% Sodium Deoxycholate, 1% NP-40, protease inhibitor cocktail and NEM). 
Samples were then incubated on ice for 30 min and cleared by centrifuging. 
Immunoprecipitation assay using anti-Ub (FK2) antibody was performed as described 
above and H3 ubiquitination was detected by Western blot using anti-H3 antibody. 
 
2.6 Chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) assay.  
ChIP assay was performed as described(129) with some modifications. Cells were cross-
linked in culture media (with 1% formaldehyde) with gentle shaking for 10min at room 
temperature and stopped by adding glycine to a final concentration of 0.125 M. Cells 
were washed with PBS three times and nuclei were isolated. Nuclei were then lysed in 
RIPA buffer with proteinase inhibitor cocktails and sonicated using Bioruptor to shear 
genomic DNA to a range of 200-1000 bps. Lysates were cleared and blocked with BSA 
(final concentration of 1mg/mL) and salmon sperm DNA (final concentration of 
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0.3mg/mL). Pre-cleaned lysates were immunoprecipitated with various antibodies, 
followed by adding protein A/G beads. Beads were washed and eluted by 400uL elution 
buffer (with 0.1 M NaHCO3, 1% SDS). The DNA was directly recovered by gel extraction 
kit (Omega) and analyzed by real-time qPCR.  
 
2.7 Chromatin immunoprecipitation followed by sequencing (ChIP-seq).  
Chromatin immunoprecipitation assay was performed using ChIP-IT High Sensitivity kit 
(Active motif) according to the manufacturer’s manual. The Illumina compatible libraries 
were prepared using DNA Library preparation kit (KAPA, KK8232), as per the 
manufacturer’s protocol. In brief, DNA was fragmented to a median size of 150bp by 
sonication. Fragmented DNA ends were polished and 5′-phosphorylated. After addition 
of 3′-A to the ends, indexed Y-adapters were ligated and the samples were PCR amplified. 
The resulting DNA libraries were quantified and validated by qPCR, and sequenced on 
Illumina’s HiSeq 2000 in a single-read format for 36 cycles. The resulting BCL files 
containing the sequence data were converted into “.fastq.gz” files and individual sample 
libraries were demultiplexed using CASAVA 1.8.2 with no mismatches. 
 
2.8 ChIP-seq data analysis.  
Briefly, 36 nucleotides (nts) sequencing data (.fastq.gz) were unachieved and imported 
to local galaxy project instance(130-132). Sequences for each sample were concatenated 
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and 3nts from both 5’ and 3’ end were trimmed off. The processed data were aligned to 
the hg19 (human) assembly using Bowtie2(133). For each sample, the ChIP-seq peak 
profiles were obtained by normalizing ChIP data to input data (mappable reads were 
normalized to 1X genome coverage of hg19) using BamCompare tool in DeepTools(134). 
The data were visualized by preparing custom track hubs on the UCSC genome browser. 
Global average profiles at TSS or enhancer regions were calculated by ComputeMatrix 
tool in DeepTools(134) and visualized by Microsoft Excel. Known enhancer regions were 
defined according to Broad ChromHMM tracks for HepG2 cells. Differential ChIP-seq 
peaks between samples were identified by Diffreps using G-test(135). Genes, the TSS of 
which was located within differential peaks, were then listed for subsequent Venn 
diagram visualization. Reviewer private access link for ChIP-seq data: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=apehcoywnhsjxcr&acc=GSE663
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2.9 RNA extraction and cDNA synthesis.  
Cells were lysed in TRIZOL reagent (Invitrogen) and extracted by chloroform. Total 
RNA were then precipitated by isopropanol and washed with 70% ethanol. cDNA were 
synthesized according to the standard M-MLV reverse transcriptase protocol. Briefly, 
total RNA were mixed with oligo(dT), dNTP, M-MLV reverse transcriptase (Invitrogen) 
in the M-MLV buffer and the reaction was performed using a thermo cycler.  
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2.10 Microarray, Gene set enrichment analysis (GSEA) and TCGA data 
analysis. 
 Total RNA was extracted and purified using RNeasy mini kit (QIAGEN) according to 
manufacturer’s manual. Microarray analysis was performed for total RNA on Illumina 
HumanHT12v4 platform following Illumina’s standard procedure. All data sets were 
normalized based on the mean value, and differentially expressed genes were ranked by 
T-test.  Gene set enrichment analysis was performed using GSEA software with KEGG 
pathway gene sets and GO term pathway gene sets respectively. Significantly enriched 
gene sets (p<0.05, q<0.25) were visualized using Cytoscape(136). TCGA exon 
expression data sets (Illumina) for various cancer types were visualized in UCSC cancer 
genome browser. Cases with highest and lowest 30% expression of NEDD4 were 
included to evaluate the correlation between the expression of NEDD4 and other genes 
by Wilcoxon test (Bonferroni correction). Exons show significant (p<0.05) correlations 
with NEDD4 expression were shown either in red (positive correlation) or green 
(Negative correlation) in the histogram. Reviewer private access link for microarray data:  
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=evazwqokhlgtbwl&acc=GSE663
41 
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2.11 In vitro binding and native gel analysis.  
Recombinant full-length GCN5 and ubiquitin were mixed in the binding buffer (25 mM 
HEPES, pH 7.4, 125 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 0.5% Triton X-100) and 
incubated on ice for 30min. Samples were then mixed with sample buffer (62.5 mM 
Tris-HCl pH6.8, 25% glycerol, 1% Bromophenol blue) or SDS sample buffer, and then 
separated by native Polyacrylamide gel electrophoresis (PAGE) or SDS-PAGE 
respectively. GCN5 and ubiquitin proteins were then detected by Western blot.  
 
2.12 In vitro tumor sphere formation and in vivo tumor engraftment assay.  
For in vitro tumor sphere forming assay, 5000 cells were seeded in the ultra-low 
attachment 6-well plate (Corning Life Science) and cultured in tumor sphere forming 
medium (DME/F12 supplemented with 5ug/mL Insulin, 0.05ug/mL hEGF and 0.5ug/mL 
Hydrocortisone). Cells were incubated at 37 °C for 13 days and spheres larger than 100um 
were counted. For in vivo tumor engraftment assay, cancer cells were first stained using 
ALDEFLUOR Kit (StemCell Technology) following manufacturer’s manual. Cells with 
top 2.5% Aldh enzymatic activity were then isolated by cell sorting using flow cytometry. 
1000 isolated cells were subcutaneously injected into each nude mouse (NCRNU-
F/Homozygous, Taconic Farms) and monitored for tumor growth for 70 days. Mice died 
tumor free were excluded from final results. 
 
	 42	
2.13 ROS and GSH detection.  
To detect cellular ROS, cells were collected and incubated with DCFDA at 37°C for 
30min and then subjected to flow cytometry analysis. ROS levels were calculated as the 
mean fluorescence signal. Cellular GSH level was determined by Glutathione assay kit 
(Sigma Aldrich, CS0260).  
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Chapter 3 Results 
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3.1 NEDD4 ubiquitinates H3 upon glucose stimulation 
By analyzing the published large-scale quantitative mass spectrometry data sets 
(124-126), we found that H3 proteins were ubiquitinated on multiple lysine (K) residues 
(Figure 1a). While these proteomic studies are mostly carried out under non-stimulus 
conditions, it is critical to know which physiological cues can drive this ubiquitination 
modification and what functions it may play. To address these questions, we challenged 
cells with various physiological stimuli and performed in vivo ubiquitination assay to 
detect ubiquitination of endogenous H3 proteins. Of these stimuli, H3 ubiquitination was 
drastically inhibited by glucose deprivation, but only slightly affected under glutamine 
deprivation or remained unaltered by other stresses, such as serum starvation, genotoxic 
stress and oxidative stress (Figure 1b and 1c). We also excluded the possibility that 
glucose starvation causes irreversible damages to the cells, thereby leading to the 
reduction of H3 ubiquitination indirectly, as add-back of glucose to cells under glucose 
deprivation readily recovered H3 ubiquitination (Figure 1d and 1e). Accordingly, these 
results suggest that glucose is a bona fide physiological activator for H3 ubiquitination.  
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Figure 1 Glucose induces H3 ubiquitination. 
 
a. Summary of H3 ubiquitination sites identified in various large-scale quantitative 
proteomics studies. 
b, c. Glucose deprivation abolished H3 ubiquitination. 293T cells were transfected with 
his-ubiquitin plasmid (His-Ub) for 36 hours and treated with various stresses for 4 hours 
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before in vivo ubiquitination assay to access the H3 ubiquitination (See experimental 
procedures for details). 
d. Feeding glucose recovered H3 ubiquitination. 293T cells were transfected with his-
ubiquitin plasmid for 36 hours, then glucose-starved for 4 hours, and added-back glucose 
for indicated times before in vivo ubiquitination assay.  
e. Glucose induces H3 ubiquitination in a time dependent manner. Hep3B cells were 
glucose starved for 4 hours and glucose was added for indicated time before chromatin 
fractionation assay. 
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We next determined which E3 ligase is responsible for glucose-induced H3 
ubiquitination.  By screening a panel of ubiquitin E3 ligases, NEDD4 (also known as 
neural precursor cell expressed developmentally down-regulated protein 4) was identified 
to be a potential E3 ligase for H3 ubiquitination, as wild-type (WT) NEDD4 could 
promote H3 ubiquitination, but not E3 ligase dead mutant NEDD4 (NEDD4-CS), (Figure 
2a to 2c). In line with this possibility, NEDD4 knockdown abolished H3 ubiquitination 
(Figure 2d). To investigate whether NEDD4 is a direct E3 ligase for H3, we performed 
in vitro ubiquitination assay by mixing recombinant active form of NEDD4 with various 
E2 ubiquitin-conjugating enzymes and histone octamer. We found that NEDD4 in 
combination with UbcH7 effectively triggered in vitro H3 ubiquitination, although 
UbcH5 a/b/c mix or UbcH6 also exhibited enzymatic activity (Figure 2e).  
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Figure 2 Nedd4 is the E3 ligase for H3. 
 
a, b. Screening of E3 ligases for H3 ubiquitination. 293T cells were transfected with his-
ubiquitin plasmid and various E3 ligases constructs for in vivo ubiquitination assay. 
E3s
His-Ub +    +    +     +    +    +     +    +    +       +    +    +     +      +    +    +    +
H3Ub1
HA-H3 
H3Ub2
H3Ub3
a
IB
:H
A/
M
yc
IB
:F
la
g
H3Ub1
HA-NEDD4 
H3 
NEDD4     - - WT  CS 
WCE 
Ni-NTA 
His-Ub - +     +     +  
c
d e
NEDD4 
H3 
H3Ub1 
His-Ub +      +    
WCE 
Ni-NTA 
b
H3 ub
H3
E3s
Ni-NTA
W
CE
E1 - + + + + + +
E2 - -
E
2 
M
ix
U
bc
H
4
U
bc
H
5
a/
b/
c
U
bc
H
7
U
bc
H
6
NEDD4 - - - + + + +
Histone octamer - + + + + + +
H3Ub1
H3Ub2
25kDa 
37kDa 
20kDa 
15kDa 
H3 (S.E.) 
H3 (L.E.) 
NEDD4
In
pu
t
(C
BB
 
sta
ini
ng
)
E2s
C2 WW HECTWWWW WWN C
Phospholipid PPXY E2
Substrate	binding Ubiquitin	 ligase	activityTargeting	E3	to	membrane
NEDD4
	 49	
c. NEDD4 E3 ligase dead mutant (CS mutant) failed to trigger H3 ubiquitination. 293T 
cells were transfected with his-ubiquitin plasmid and WT NEDD4 or NEDD4 CS mutant 
construct for in vivo ubiquitination assay.  
d. NEDD4 knockdown abolished H3 ubiquitination. Control and NEDD4 knockdown 
293T cells were transfected with his-ubiquitin plasmid for in vivo ubiquitination assay. 
e. NEDD4 ubiquitinated H3 in vitro. In vitro ubiquitination assay was performed for 
recombinant NEDD4 and histone octamer (See experimental procedures for details). 
Reaction products were then assessed by Western blot using anti H3 antibody. H3 mono- 
and di-ubiquitination have predicted molecular weights of ~25kDa and ~33kDa. S.E. and 
L.E. are short for shorter exposure time and longer exposure time respectively. 
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Next we investigated whether NEDD4 is required for glucose-induced H3 
ubiquitination. By performing endogenous ubiquitination assay, we found that NEDD4 
knockdown or knockout abolished endogenous H3 ubiquitination induced by glucose 
treatment (Figure 3a and 3b), indicating a physiological role of NEDD4 in mediating 
glucose-induced H3 ubiquitination. We further asked the question whether the glucose 
levels could orchestrate E3 ligase activity of NEDD4. Our data showed that NEDD4 
overexpression failed to trigger H3 ubiquitination under glucose deprivation, whereas 
add-back of glucose readily rescued NEDD4 overexpression induced H3 ubiquitination 
(Figure 3c). As we have also noticed that H3 ubiquitination in some of our experiments 
displayed multiple ubiquitination bands at higher molecular weight, we sought to test 
whether H3 undergoes poly-ubiquitination or multi-mono-ubiquitination. We found that 
ubiquitin with its all K mutated to R (Ub K0) did not affect H3 ubiquitination pattern in 
the in vivo ubiquitination assay (Figure 3d), indicating that NEDD4 mono-ubiquitinates 
H3 at multiple sites. Moreover, while NEDD4 is previously shown to regulate protein 
mostly in the cytosol and plasma membrane, a few nuclear substrates for NEDD4 are 
found(137, 138). Consistently, we found that NEDD4 could be detected both in cytosol 
and nucleus by using biochemical fractionation and immunofluorescence assays (Figure 
3e and 3f), suggesting that NEDD4 can target its protein substrates in the nucleus such as 
H3. Collectively, these data provide strong evidence that NEDD4 is a direct E3 ligase and 
responsible for glucose-induced H3 ubiquitination.
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Figure 3 Glucose induced H3 ubiquitination is Nedd4 dependent. 
 
a, b. NEDD4 knockdown or knockout abolished glucose-induced H3 ubiquitination. 
Hep3B cells were glucose starved for 4 hours and added-back glucose for 2 hours before 
endogenous ubiquitination assay (see experimental procedures for details). H3 
ubiquitination was then visualized by Western blot.  
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c. Add-back of glucose recovered NEDD4 overexpression induced H3 ubiquitination. 
293T cells were transfected with his-ubiquitin and NEDD4 plasmids for 36 hours, then 
glucose-starved for 4 hours, and added-back glucose for indicated times before in vivo 
ubiquitination assay.  
d. NEDD4 triggered mono-ubiquitination on H3. 293T cells were transfected with Flag-
H3, HA-NEDD4, His-Ub WT and His-Ub K0 as indicated before in vivo ubiquitination 
assay.  
e. Cellular fractionation was performed for control and NEDD4 knockdown Hep3B cells.  
f. Immunofluorescence assay was performed for Hep3B cells. The intensity of NEDD4 
staining (Green) and DAPI staining (Blue) along the yellow line in the image was shown 
in the histogram. 
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To understand how glucose promoted NEDD4 mediated H3 ubiquitination, we 
speculated that glucose treatment might activate NEDD4 through altering the post-
translational modification status of NEDD4. As glucose treatment could elevate the 
cellular level of ATP and acetyl-CoA, which are important cofactors for protein 
phosphorylation and acetylation, we evaluated overall phosphorylation and acetylation of 
NEDD4 protein. Interestingly, we found that tyrosine phosphorylation of NEDD4, but 
not NEDD4 serine/threonine and acetylation, is strongly induced by glucose treatment 
(Figure 4a). As a previous report shown that growth factor mediated NEDD4 
phosphorylation at tyrosine (Y) 43 and Y585 promotes NEDD4 E3 ligase activity (112), 
we examined whether glucose also induced NEDD4 phosphorylation at tyrosine (Y) 43 
and Y585 and found that mutating Y43/585 to phenylalanine (F) blocked glucose induced 
NEDD4 tyrosine phosphorylation (Figure 4b), indicating that glucose induces NEDD4 
tyrosine phosphorylation at Y43 and Y585, which may then activate NEDD4 through 
Y43/585 phosphorylation. In support of this notion, NEDD4 Y43/585F mutant failed to 
trigger H3 ubiquitination, but phosphorylation mimetic mutant Y43/585E enhanced H3 
ubiquitination more efficiently than WT NEDD4 (Figure 4c). Importantly, Y43/585E 
mutant rescued H3 ubiquitination under glucose deprivation to the level similar to that 
triggered by WT NEDD4 in glucose-stimulated conditions (Figure 4d). Collectively, our 
results suggest that glucose induces NEDD4 activation by inducing NEDD4 tyrosine 
phosphorylation at Y43 ad Y585, in turn leading to H3 ubiquitination.  
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Figure 4 Glucose induces the tyrosine phosphorylation of Nedd4. 
 
a. 293T cells transfected with HA-NEDD4 was treated with glucose and harvested for 
immunoprecipitation assay.  
b. Glucose induced NEDD4 phosphorylation at Y43 and Y585. 293T cells transfected 
with WT or Y43/585F NEDD4 plasmids were treated with glucose and harvested for IP. 
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c. NEDD4 phosphorylation is required for H3 ubiquitination. 293T cells transfected with 
WT, Y43585F or Y43/585E NEDD4 plasmids were harvested for in vivo ubiquitination 
assay.  
d. 293T cells were transfected with His-Ub and indicated plasmids and treated with 
glucose before in vivo ubiquitination assay. 
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3.2 Glucose-induced H3 K23/36/37 ubiquitination by NEDD4 is required for 
H3 K9 and K14 acetylation 
Next we determined whether NEDD4 mediated H3 ubiquitination regulates H3 
acetylation. Similar to H3 ubiquitination, we found that glucose treatment readily induced 
H3 acetylation on K9, K14, K27 and K56 sites, but had no effect on H3 phosphorylation, 
H3 di- and tri-methylation or H3 acetylation at other lysine sites (Figure 5a to 5e). Notably, 
NEDD4 knockdown or knockout specifically impaired glucose-induced H3 acetylation, 
but not other H3 modifications (Figure 5a to 5e), suggesting that there is a link between 
H3 ubiquitination and H3 acetylation under glucose stimulation.  
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Figure 5 Nedd4 is required for glucose induced H3 acetylation. 
a. NEDD4 knockdown abolished glucose-induced H3 K9, K14, K27 and K56 acetylation. 
Control and NEDD4 knockdown Hep3B cells were glucose-starved for 4 hours, and 
added-back glucose for 3 hours before whole cell extraction for Western blot analysis 
(See experimental procedures for details). A. E. is short for acid extraction. 
b, c. Quantification of Western blot data (n=3, mean ± S.D.).  
d, e. NEDD4 deficient iMEF cells or MDA231 cells were treated with glucose and 
harvested for Western blot analysis.    
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While mammalian H3 contains three isoforms (H3.1, H3.2 and H3.3), H3.3 is 
found to be the major isoform decorated by H3 acetylation(139). Consistent with the 
previous findings, we demonstrated that H3.3 knockdown abolished H3 acetylation on 
K4, K9, K14, K23, K27 and K56, but not K18 and K36 (Figure 6a). Similar to NEDD4 
knockdown and glucose stimulation, H3.3 knockdown also did not alter H3 methylation 
(Figure 6a). We then used H3.3 to determine NEDD4 dependent ubiquitination sites on 
H3. After serial mutagenesis on all H3.3 lysine residues, we found that mutation of K23 
or K36/37 effectively blocked glucose- and NEDD4-mediated H3.3 ubiquitination 
(Figure 6b to 6d), suggesting that NEDD4 specifically ubiquitinates H3 on K23, K36 and 
K37 residues. The existence of endogenous ubiquitination modification on these sites was 
also supported by previous large-scale quantitative mass spectrometry analysis(125, 126). 
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Figure 6 Nedd4 ubiquitinates H3 at K23/36/37 residues. 
a. H3.3 knockdown abolished H3 K9, K14, K27 and K56 acetylation. Control and H3.3 
knockdown Hep3B cells were lysed for Western blot analysis. 
b. H3 K23R and K36/37R mutant abolished glucose induced H3 ubiquitination. Hep3B 
cells expressing various Flag-H3.3 constructs were glucose-starved for 4 hours and 
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added-back glucose for 2 hours before chromatin fractionation assay. Ubiquitination 
levels were normalized to input (n=5, mean ± S.E.M.). N.S. is short for non-specific band. 
c. H3 K23 and K36/37R mutant abolished NEDD4 overexpression induced H3 
ubiquitination. 293T cells were transfected with his-ubiquitin, NEDD4 plasmids and 
various Flag-H3.3 constructs for 36 hours before in vivo ubiquitination assay. 
Ubiquitination levels were normalized to input. 
d. Chromatin fractionation was performed for Hep3B cells stably expressing Flag-H3.3 
WT or K23/36/37R. NEM was added to preserve ubiquitination. 
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To determine the causal relationship between H3 ubiquitination and acetylation, 
we stably expressed WT H3.3 and H3.3 ubiquitination-deficient mutant in Hep3b cells to 
examine H3 acetylation. Consistent with the effect of glucose and NEDD4 on H3 
acetylation, H3.3 K23/36/37R mutant displayed impaired H3 acetylation on K9 and K14 
(Figure 7a to 7d), while single or double mutation also displayed partial effect on H3 
acetylation (Figure 7e).  
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Figure 7 H3 ubiquitination is required for H3 acetylation. 
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a, b.  H3 K23/36/37R is defect in H3 K9/K14 acetylation. WT or K23/36/37R Flag-
H3.3 was stably expressed in Hep3B cells and immunoprecipitated for Western blot 
analysis. 
c, d. Quantification of Western blot data (n=3, mean ± S.D.).  
e. Various mutants of Flag-H3.3 were restored in shH3.3 Hep3B cells. 
Immunoprecipitation assay was used to access the H3 K9ac.   
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Additionally, we performed a kinetic study for H3 ubiquitination and K9 
acetylation to further elucidate their regulation.  Adding back glucose readily induced H3 
ubiquitination within 1 hour, while acetylation of H3 at K9 occurred around 2 hours 
(Figure 8a), indicating H3 ubiquitination occurs earlier than H3 K9 acetylation and could 
be upstream of H3 acetylation. To test whether NEDD4 tyrosine phosphorylation at Y43 
and Y583 plays a critical role in H3 acetylation, we restored NEDD4 WT, Y43/585F and 
Y43/585E mutant in the NEDD4 knockdown cells to examine their effect on H3 
acetylation. We found that NEDD4 Y43/585F mutant failed to rescue glucose induced 
H3 K9 acetylation, but NEDD4 Y43/585E mutant fully rescued glucose-induced H3 K9 
acetylation and executed such effect even more efficiently than NEDD4 WT (Figure 8b), 
confirming that glucose activated NEDD4 through NEDD4 tyrosine phosphorylation. 
Taken together, our data suggest that glucose-induced H3 ubiquitination by NEDD4 
selectively regulates H3 acetylation.  
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Figure 8 Nedd4 activity is important for H3 acetylation. 
a. Hep3B cells treated with glucose for various times were harvested for 
immunoprecipitation assay. Kinetics of H3 ubiquitination and K9ac were shown in log 
scale. 
b. NEDD4 knockdown Hep3B cells transfected with WT, Y43/585E or Y43/585F 
mutant were treated with glucose and harvested for Western blot analysis.  
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whether glucose per se is critical for NEDD4 mediated H3 ubiquitination. We treated 
cells with ATP, pyruvate or NADH, which can be uptake by cells, and found that none 
of them can rescue the impact of glucose deprivation on H3 ubiquitination, H3 K9 
acetylation and NEDD4 phosphorylation (Figure 9a and 9b), indicating that metabolites 
upstream of pyruvate or glucose per se may promote NEDD4 phosphorylation and 
activity through an unknown mechanism. Given the fact that acetyl-CoA is crucial for H3 
acetylation and pyruvate can be converted to acetyl-CoA, our surprising observation that 
pyruvate cannot fully activate H3 K9 acetylation further demonstrated the necessity of 
H3 ubiquitination to trigger glucose-induced H3 acetylation (Figure 9a). Of note, ATP 
(or pyruvate/NADH, which can also generate ATP) could partially enhance H3 
ubiquitination but not NEDD4 phosphorylation (Figure 9b), suggesting that this ATP 
dependent ubiquitination reaction may also be highly sensitive to cellular ATP level. In 
line with this observation, glucose treatment, which can strongly induce cellular ATP 
level, further enhances H3 ubiquitination triggered by active NEDD4 Y43/585E mutant 
(Figure 4d), implying that both ATP level and E3 ligase activity of NEDD4 could regulate 
H3 ubiquitination. However, without Acetyl-CoA generated by glucose, ATP, NADH or 
active NEDD4 mutant alone could not rescue H3 acetylation (Figure 9a). These results 
collectively depict a previously unexpected model of glucose action, which regulates H3 
acetylation through not only acetyl-CoA, but also H3 ubiquitination driven by glucose 
mediated ATP production and NEDD4 activation.  
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Figure 9 Nedd4 is activated by glucose but not ATP, pyruvate or NADH. 
a. 293T cells transfected with his-Ub and treated with various metabolites were harvested 
for in vivo ubiquitination assay.  
b. 293T cells treated with various metabolites were harvested for immunoprecipitation 
assay. 
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3.3 NEDD4 is required for glucose-induced H3 K9 acetylation at TSS and 
enhancers 
H3 K9 acetylation is known to localize at the TSS and generally regulates gene 
transcription in mammalian cells(140). Having shown that glucose treatment increases 
total or cellular level of H3 K9 acetylation in a NEDD4 dependent manner, we asked 
whether this process is gene-specific. Therefore, genome-wide pattern of H3K9 
acetylation was determined by ChIP-seq assay. Consistent with Western blot result, we 
found that glucose globally enhanced H3 K9 acetylation at TSS of genes and such effect 
was impaired upon NEDD4 knockdown by ChIP-seq assay (Figure 10a). Our results also 
indicated that glucose specifically induces H3 K9 acetylation at TSS of around 2000 
genes, and 40% of those acetylation events were NEDD4 dependent (Figure 10b and 10c), 
highlighting the critical role of NEDD4 in glucose-induced H3 K9 acetylation at TSS. 
Meta-analysis also revealed that glucose promoted H3 K9 acetylation on known 
enhancers, and this event was also NEDD4-dependent (Figure 10d), suggesting that 
NEDD4 may also participate in the activation of enhancers in response to glucose 
stimulation. Together, these data provide further evidence to support that NEDD4 
regulates glucose-induced H3 K9 acetylation at TSS and enhancers. 
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Figure 10 Nedd4 is required for glucose induced H3 acetylation at TSS and 
enhancers. 
NEDD4 knockdown impaired glucose-induced genome-wide H3 K9 acetylation at TSS 
and enhancer regions. ChIP-seq was performed for control and NEDD4 knockdown 
Hep3B cells before or after adding-back of glucose for 3 hours. Shown were global H3 
K9ac profiles at TSS (a), Venn diagram of genes with differential H3 K9ac peaks at TSS 
under various conditions (b and c) and global H3 K9ac profiles at known enhancers (d). 
See experimental procedures for details. 
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3.4 Glucose-induced H3 ubiquitination by NEDD4 regulates gene transcription 
We next determined whether glucose-induced H3 ubiquitination by NEDD4 
regulates transcription, and if so, whether NEDD4 regulates gene transcription through 
H3 K9 acetylation. To this end, genome-wide differential gene expression pattern was 
determined by gene expression microarray. Integrative analysis of microarray and ChIP-
seq data sets revealed that NEDD4 knockdown caused down-regulation of around 5,000 
genes, and 50% of these genes showed reduced H3 K9 acetylation at TSS upon NEDD4 
knockdown (Figure 11a and 11b). Additionally, we applied GSEA (141, 142) (gene set 
enrichment analysis) using modified Kolmogorov–Smirnov (K-S) test to evaluate the 
statistical relationship between H3 K9 acetylation and gene expression regulated by 
NEDD4. The K-S test showed a significant positive correlation (P<0.05) between 
NEDD4-dependent H3 K9 acetylation at TSS and NEDD4-regulated gene transcription 
(Figure 11c), suggesting that NEDD4 orchestrates gene transcription by regulating H3 
K9 acetylation at TSS. We then used qPCR to validate the expression of top list genes 
from microarray and showed that NEDD4 deficiency indeed inhibited their expression 
(Figure 11d and 11e).  
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Figure 11Nedd4 mediated H3 acetylation is required for gene expression. 
a-c. NEDD4 regulates H3 K9ac at TSS of NEDD4 target genes. Shown were Venn 
diagram of genes with differential expression or differential H3 K9ac at TSS. GSEA was 
performed to evaluate the distribution of genes that show down-regulation of H3K9ac at 
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TSS in NEDD4 knockdown cells in microarray-derived gene list, which is rank ordered 
either by T-test or fold change. 
d. Heat map view of top and bottom gene list of microarray data sets. Microarray analysis 
for total RNA was performed for control and NEDD4 knockdown Hep3B cells. 
e. qPCR was performed to analyze the mRNA level in NEDD4 deficient iMEFs or Hep3B 
cells (n=3, mean ± S.E.M.). 
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Among those tested genes, IL1α, IL1β and GCLM were most affected and 
regulated by glucose (Figure 12a to 12c). ChIP-seq assay revealed that H3 K9 acetylation 
at TSS of IL1α, IL1β and GCLM was induced by glucose in a NEDD4-dependent manner 
(Figure 12d and 12i). Consistently, ChIP-qPCR analysis confirmed this result in both 
NEDD4 knockdown and Nedd4-/- MEFs  (Figure 11e to 11g). In addition, we found that 
RNA polymerase II binding at TSS of IL1α and IL1β was induced by glucose in a 
NEDD4-dependent manner (Figure 11h). As H3.3 ubiquitination affects H3 K9/K14 
acetylation, we determined whether H3.3 and its ubiquitination are required for the 
transcription of IL1α, IL1β and GCLM.  
 
 
	 75	
	
Figure 12 IL1A, IL1B and GCLM are glucose inducible target genes of Nedd4. 
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a. NEDD4 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was 
performed to analyze the mRNA level in control and NEDD4 knockdown Hep3B cells 
(n=3, mean ± S.E.M.). 
b. IL1α, IL1β and GCLM were induced by glucose. Hep3B cells were glucose-starved 
for 4 hours and added-back glucose for 6 hours before qPCR analysis (n=3, mean ± 
S.E.M.). 
c. qPCR was performed to analyze the mRNA level in NEDD4 deficient iMEFs or Hep3B 
cells (n=3, mean ± S.E.M.). 
d. UCSC genome browser view of ChIP-seq H3 K9ac signals along IL1B gene. 
e. NEDD4 knockdown impaired H3 K9ac at TSS of IL1a IL1b and GCLM genes. 
ChIP-qPCR using anti-H3 K9ac antibody was performed for control and NEDD4 
knockdown Hep3B cells (n=3, mean ± S.E.M.). 
f. H3 K9ac was induced at TSS of IL1 a IL1b and GCLM genes by glucose. Hep3B 
cells were glucose-starved for 4 hours and added-back glucose for 6 hours before ChIP-
qPCR analysis using anti-H3 K9ac antibody (n=3, mean ± S.E.M.). 
g. ChIP-qPCR was performed for WT and Nedd4-/- iMEFs. 
h. NEDD4 knockdown impaired glucose-induced polymerase II (pol II) binding at TSS 
of IL1Aand IL1B genes. Control and NEDD4 knockdown Hep3B cells were glucose-
starved for 4 hours and added-back glucose for 6 hours before ChIP-qPCR analysis using 
anti-pol II antibody (n=3, mean ± S.E.M.). 
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i. UCSC genome browser view of ChIP-seq H3 K9ac signals along IL1A and GCLM 
genes. 
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Knockdown of H3.3 decreased the mRNA level of IL1α, IL1β and GCLM (Figure 
13a), and such defects could be rescued by the restoration of WT H3.3, but not H3.3 
K23/36/37R mutants (Figure 13b to 13d). We also found that restoration of single or 
double mutations of H3.3 partially rescued gene expression (Figure 13e and 13f).  There 
data underpin the function of H3 ubiquitination by NEDD4 in transcription activation.  
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Figure 13 H3 ubiquitination is required for gene expression. 
0
0.2
0.4
0.6
0.8
1
1.2
IL1a IL1b GCLM
shLuc shH3.3
R
el
at
iv
e 
fo
ld
IL1α IL1β GCLM
0
5
10
15
20
25
IL-1a IL-1b GCLM
shH3.3+vector
shH3.3+H3.3 WT
shH3.3+H3 K23/36/37R
Re
la
tiv
e 
fo
ld
.3 K2 /36/37R
I α IL β GCLM
a b
IP
:F
lag
Input ChIP
Flag-H3 
Flag-H3.3   Vec WT 3KR Vec WT 3KR 
IL1A 
IL1B 
GCLM 
c d
Flag-H3.3    V   WT 3KR
Flag-H3.3 
shH3.3 
Actin
WT
K2
3R
K3
6R
K2
3/3
7R
K2
3/3
6/3
7R Ve
c
0.0
0.5
1.0
IL1a
R
el
at
iv
e 
fo
ld
WT
K2
3R
K3
6R
K3
6/3
7R
K2
3/3
6/3
7R Ve
c
0.0
0.5
1.0
IL1b
R
el
at
iv
e 
fo
ld
e f
	 80	
a. H3.3 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was performed 
to analyze the mRNA level in control and H3.3 knockdown Hep3B cells (n=3, mean ± 
S.E.M.). 
b. H3 ubiquitination deficiency impaired IL1α, IL1β and GCLM expression. qPCR was 
performed to analyze the mRNA level in vector, H3.3 WT and H3.3 K23/36/37R mutant 
restored H3.3 knockdown Hep3B cells (n=3, mean ± S.E.M.). 
c, d. Shown are Flag-H3.3 WT and K23/36/37R restoration efficiency (a) and chromatin 
integration efficiency (b) in H3.3 knockdown Hep3B cells. 
e, f. qPCR was used to analyze IL1a and IL1b mRNA level in Hep3B cells restored with 
various H3.3 constructs. 
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3.5 H3 ubiquitination specifically recruits GCN5 for H3 acetylation 
 To decipher the underlying mechanism by which H3 ubiquitination regulates H3 
acetylation, we determined whether H3 ubiquitination is crucial for the recruitment of 
chromatin remodeling complexes containing acetyltransferase activity. By analyzing 
microarray data sets against published ChIP-seq tracks for various chromatin binding 
factors(143), we identified GCN5, a histone acetyltransferase that preferentially 
catalyzes H3 K9 and K14 acetylation in mammalian cells, may be a potential candidate 
to mediate the unidirectional crosstalk between H3 ubiquitination and acetylation 
(Figure 14a). We then provided a series of experimental evidence to further confirm this 
notion.  First, we found that the mRNA level of IL1α, IL1β and GCLM was reduced 
upon GCN5 knockdown (Figure 14b), similar to the effect of glucose deprivation, 
NEDD4 knockdown and H3 ubiquitination deficiency. Second, knockdown of GCN5 
selectively impaired H3 acetylation on K9, K14, K27 and K56 (Figure 14c to 14e), but 
failed to affect H3 acetylation on other sites and H3 methylation, phenocopying the 
effect of NEDD4 knockdown.	
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Figure 14 Gcn5 is the potential HAT regulated by Nedd4. 
a. GCN5 is predicted as one of the potential regulator for NEDD4 target genes. Top 5000 
up-regulated genes from microarray data sets in Fig. 4D were included to predict potential 
regulators by using iRegulon software. See experimental procedures for details.  
b. GCN5 knockdown impaired IL1α, IL1β and GCLM expression. qPCR was performed 
to analyze the mRNA level in control and GCN5 knockdown cells (n=3, mean ± S.E.M.). 
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c. GCN5 knockdown abolished glucose-induced H3 K9, K14, K27 and K56 acetylation. 
Control and GCN5 knockdown Hep3B cells were glucose-starved for 4 hours and added-
back glucose for 2 hours before whole cell extraction for Western blot analysis.  
d. Control and GCN5 knockdown MDA 231 cells were treated with glucose and 
harvested for Western blot analysis.  
e. GCN5 is not required for H3 di-methylation. Control and GCN5 knockdown Hep3B 
cells were glucose-starved for 4 hours and added-back glucose for 2 hours before whole 
cell extraction for Western blot analysis. 
 
 
  
	 84	
Third, we found that NEDD4 knockdown impaired the interaction between H3 and GCN5 
by using the reciprocal immunoprecipitation assays (Figure 15a and 15b). Notably, GCN5 
preferentially binds to mono-ubiquitinated H3 in vivo, indicating that H3 ubiquitination 
facilitates the recruitment of GCN5 to H3 (Figure 15a). Fourth, we demonstrated that 
glucose induced the interaction between H3 and GCN5 in a H3 ubiquitination-dependent 
manner (Figure 15c). Moreover, we showed that recombinant GCN5, when mixing with 
ubiquitin in vitro, could interact with ubiquitin efficiently (Figure 15e), demonstrating 
that H3 ubiquitination serves as a molecular scaffold to recruit GCN5 to H3. Finally, by 
sequential purification assay, we demonstrated that GCN5 and ubiquitinated H3 formed 
complex in vivo (Figure 15d), further supporting the interaction between GCN5 and 
ubiquitinated H3. To determine whether there is a putative ubiquitin binding motif on 
Gcn5, we have created different truncated Gcn5 mutants (Δ aa1-485, Δ aa485-650, Δ 
aa650-837) and purified them for in vitro binding assay by mixing with recombinant 
GST-ubiquitin proteins. Our data showed that Δ aa485-650 of Gcn5 did not bind to 
ubiquitin, while other mutants did bind to ubiquitin, suggesting that aa485-650 of Gcn5 
is required for ubiquitin binding (Figure 15f and 15g). These data indicate that aa485-650 
may contain a putative ubiquitin-binding region.  
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Figure 15 H3 ubiquitination is required for the recruitment of Gcn5. 
a, b. NEDD4 knockdown impaired the interaction between GCN5 and H3.3. Transfected 
Flag-H3.3 or Flag-GCN5 in Hep3B cells was immunoprecipitated to analyze its co-
immunoprecipitates by Western blot.  
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c. H3 ubiquitination deficiency impaired the interaction between GCN5 and H3.3. Hep3B 
cells were transfected with Flag-H3.3 WT or K23/36/37R for 36 hours, then glucose-
starved for 4 hours and added-back glucose for 2 hours. Cells were then lysed for co-
immunoprecipitation assay using anti-Flag antibody and subsequent Western blot 
analysis.  
d. GCN5 and ubiquitinated H3 form complex in vivo. 293T cells were transfected with 
Flag-GCN5 and His-Ub as indicated. Briefly, sequential purification is done by first IP 
with Flag antibody from whole cell extracts in RIPA buffer. Immunoprecipitates were 
then released from antibody/beads by buffer A and followed by in vivo ubiquitination 
assay for endogenous H3.  
e. GCN5 formed complex with ubiquitin in vitro. See experimental procedures for details.  
f, g. Various truncated Flag-GCN5 were purified from mammalian cells for the in vitro 
binding assay with GST-Ub.   
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To comprehensively understand the dynamic recruitment of acetyltransferase by 
H3 ubiquitination, we also examined the recruitment of other known H3 
acetyltransferases, p300 and PCAF, by co-immunoprecipitation assay. However, we 
found there is no obvious difference between the interaction of p300 or PCAF with WT 
H3 and H3 K23/36/37R mutant (Figure 16). In addition, we did not find that NEDD4 
knockdown or H3.3 K23/36/37R mutation reduces H3.3 localization on the TSS of IL1A, 
IL1B and GCLM genes, which might affect H3 acetylation and gene transcription (Figure 
17a to 17c). Also, GCN5 knockdown did not affect H3 ubiquitination (Figure 17d). 
Collectively, these results suggest that glucose-induced H3 ubiquitination by NEDD4 
specifically regulates the recruitment of GCN5 to H3 for acetylation during transcription.  
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Figure 16 H3 ubiquitination on K23/36/37 sites is not required to recruit p300 or 
pCAF to histone H3.3. 
Stably expressed Flag-H3.3 WT or K23/36/37R was immunoprecipitated from Hep3B 
cells to analyze its co-immunoprecipitates by Western blot. 
  
pCAF
Flag-H3.3
pCAF
p300
Flag-H3
p300
W
CE
 
IP
: F
lag
 1 0.91
1 1.39
Binding ratio
Binding ratio
	 89	
Gene-specific regulation is usually achieved by the recognition of cis-regulatory 
elements on the genome, like glucose responsive elements by trans-regulatory elements, 
including glucose activated transcription factors and chromatin remodeling factors. To 
know whether NEDD4 conveys gene-specific effect for H3 acetylation, we determined 
whether NEDD4 resides in the TSS of its target genes. Chromatin fractionation and ChIP-
seq assays revealed that NEDD4 does not display chromatin binding (data not shown). 
Since H3 ubiquitination is also enriched in nucleoplasm (Figure 17e), H3 ubiquitination 
by NEDD4 likely occurs outside of chromatin and gene specificity is likely not conveyed 
by the binding of NEDD4 to specific genomic locus. We also asked whether histone 
chaperones, which are involved in the nucleosome assembly in the nucleoplasm, regulate 
H3 ubiquitination and acetylation. Knockdown of HIRA, the major histone chaperone for 
H3.3, did not alter glucose induced H3 ubiquitination and H3 K9 acetylation (Figure 17f), 
ruling out the possibility that glucose induced H3 ubiquitination regulates H3 acetylation 
and gene transcription through affecting nucleosome assembly and histone deposition. Of 
note, disabling H3.3 deposition by HIRA knockdown did not affect glucose induced H3 
K9 acetylation (Figure 17f), suggesting that glucose driven H3 acetylation may also occur 
mainly in the nucleoplasm. Moreover, NEDD4 knockdown did not affect the binding 
between H3.3 and HIRA (Figure 17g). These observations well support our model that 
NEDD4 ubiquitinates H3 in the nucleoplasm and in turn regulates H3 acetylation, as 
glucose induced H3 ubiquitination is upstream of glucose induced H3 acetylation 
occurred in the nucleoplasm. 
	 90	
Although NEDD4 ubiquitinates H3 in the nucleoplasm, we could detect H3 
ubiquitination on chromatin and the localization of H3 ubiquitination at TSS of IL1A, 
IL1B and GCLM by sequential ChIP assay (Figure 17h), indicating that ubiquitinated H3 
could be deposited into chromatin. Knockdown of NEDD4, which abolished H3 
ubiquitination, also blocked glucose induced GCN5 recruitment to chromatin (Figure 17i), 
implying that H3 ubiquitination, once deposited into chromatin, may also regulate GCN5 
recruitment for glucose induced H3 acetylation at chromatin level. 
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Figure 17 H3 ubiquitination occurs at nucleoplasm and does not affect the 
incorporation of H3.3.  
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a-c. ChIP-qPCR was performed for control and NEDD4 knockdown Hep3B cells.  
d. GCN5 knockdown Hep3B cells were subjected to endogenous ubiquitination assay.  
e. Immunoprecipitation assay was performed for the Hep3B cells with glucose 
treatment.  
f. In vivo ubiquitination assay was performed for control and HIRA knockdown Hep3B 
cells treated with glucose.  
g. Immunoprecipitation assay was performed for control and NEDD4 knockdown 
Hep3B cells.  
h. Sequential ChIP assay was performed using Re-ChIP-IT→ kit (Active Motif, anti-H3 
(Abcam, ab12079), anti-Ub (Thermo scientific, 10H4L21)).   
i. Hep3B cells were treated with glucose for indicated times before chromatin 
fractionation. 
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3.6 Glucose induced H3 ubiquitination by NEDD4 is required for the tumor 
sphere formation and tumor engraftment 
To understand the biological significance of glucose-induced H3 ubiquitination 
by NEDD4, we applied Gene Set Enrichment Analysis (GSEA) to discover enriched gene 
sets in microarray data sets. We found that knockdown of NEDD4 profoundly impaired 
multiple cancer-related pathways(136) (Figure 18a to 18c), indicating the potential role 
of NEDD4 in cancer(115). To evaluate the clinical relevance of this finding, we analyzed 
the TCGA exon expression data sets for NEDD4 and top-ranked genes in cancer-related 
pathways from microarray (Figure 19a). We found that in multiple cancer types their 
expressions were significantly (p<0.05) positively correlated (Figure 19b).  
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Figure 18 Nedd4 target genes are enriched for cancer pathways. 
a. Multiple functional gene sets are enriched in control versus NEDD4 knockdown 
Hep3B cells.  
b, c. Enrichment map view of gene set enrichment analysis results. 
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Figure 19 Nedd4 target genes is correlated with Nedd4 in the TCGA data sets. 
a. Heat map view of top gene list of cancer-related gene sets.  
b. Heat map view of the TCGA exon expression profile for the NEDD4 and NEDD4 
target genes from cancer-related gene sets. Patient samples ranked tops or bottoms 30% 
for NEDD4 expression were included and rank listed. Wilcoxon test was performed to 
evaluate the correlation of gene expression between NEDD4 and each gene. Significant 
(p<0.01) positive correlations were shown in red and negative correlations were show in 
green.  
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This observation led us to hypothesize that glucose-induced H3 ubiquitination by 
NEDD4 may have a critical role in cancer regulation. To test this hypothesis, we 
determined whether Aldh+ population and sphere forming ability are affected by glucose-
induced H3 ubiquitination by NEDD4. Notably, we found that in vitro tumor sphere 
numbers and Aldh+ cell population were reduced upon glucose depletion, NEDD4 
knockdown, NEDD4 tyrosine phosphorylation deficient mutation, GCN5 knockdown, 
H3.3 knockdown and deficiency of H3 ubiquitination (Figure 20a to 20p).  
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Figure 20 H3 ubiquitination is required for the maintenance of cancer stem cells. 
a. Glucose deprivation abolished in vitro tumor sphere formation for Hep3B cells. 
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b-p. NEDD4, H3.3, Gcn5, H3 ubiquitination and Nedd4 phosphorylation are required for 
in vitro tumor sphere formation and maintaining Aldh+ cell population. Cells were 
analyzed by in vitro tumor sphere forming assay (See experimental procedures for details). 
Data were presented as the mean number of three biological replicates ± S.E.M. Cells 
were stained for Aldh enzymatic activity and analyzed by flow cytometry. Data were 
presented as the mean percentage of three biological replicates ± S.E.M. 
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To further examine the in vivo function, 1000 Aldh+ cells were subcutaneously 
injected into nude mice to evaluate the in vivo tumor engraftment frequency. We found 
that knockdown of NEDD4 or H3 K23/36/37R mutation reduced the tumor incidence and 
average tumor size, suggesting that NEDD4-mediated H3 ubiquitination is also required 
for the tumorigenecity of Aldh+ cells in vivo (Figure 21a to 21h). Together, these studies 
reveal an important role of glucose-induced H3 ubiquitination by NEDD4 in cancer 
development.  
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Figure 21 H3 ubiquitination is required for the in vivo engraftment of cancer stem 
cells. 
a-c. NEDD4 knockdown reduced in vivo tumor engraftment frequency. Shown were 
tumor image, tumor incidence and tumor size, which was presented as the mean volume 
of tumors ((L x W x W)/2) ± S.E.M. See experimental procedures for details.  
d-f. K23/36/37R mutation reduced in vivo tumor engraftment frequency. Shown were 
tumor image, tumor incidence and tumor size, which was presented as the mean volume 
of tumors ((L x W x W)/2) ± S.E.M. See experimental procedures for details.  
g, h. Shown are the mice image of xenograft model. 
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3.7 IL1α/IL1β and reaction oxygen species (ROS) homeostasis are critical 
for tumor sphere formation 
We next determined which set of target genes is involved in tumor sphere 
formation. As we have already identified IL1α, IL1β and GCLM as transcriptional targets 
(Fig. 4e and 4l), we investigated whether any of these genes may be involved in tumor 
sphere formation. While neutralizing extracellular IL1α and IL1β individually had little 
impact on tumor sphere formation in vitro, simultaneous sequestering of IL1α and IL1β 
resulted in a drastic reduction of tumor sphere numbers (Figure 22a and 22c), suggesting 
that IL1α and IL1β are required, but likely compensate each other, for maintaining tumor 
sphere formation ability. Interestingly, we also found that the treatment of IL1β could not 
fully rescue the defect in tumor sphere formation upon NEDD4 knockdown, despite that 
IL1β alone readily increased the tumor sphere numbers in control cells (Figure 22b and 
22d), indicating that there are other important factors involved. As excess of ROS has 
deleterious impact on cancer cells(144), we rationalized that loss of GCLM, which is a 
key enzyme subunit in the biosynthesis of anti-oxidant glutathione (GSH), may lead to 
ROS elevation and subsequent inhibition of tumor sphere formation. In line with this 
assumption, we found that the knockdown of NEDD4 or deficiency of H3 ubiquitination, 
which impaired GCLM expression, increased cellular ROS level and decreased GSH 
level (Figure 22e to 22g). Treatment of NAC, a widely used ROS scavenger, not only 
increased tumor sphere number in control cells, but also partially rescued NEDD4 
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knockdown phenotype (Figure 22b and 22d). Remarkably, co-administration of NAC and 
IL1β completely rescued the defect in tumor sphere formation upon NEDD4 knockdown 
(Figure 22b and 22d), suggesting both IL1β and anti-oxidant are critical for tumor sphere 
formation. Together, these results reveal that IL1α, IL1β and GCLM are critical 
downstream mediators of H3 ubiquitination signaling in cancer regulation.  
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Figure 22 IL1A, IL1B and GCLM are important cancer stem cell factors. 
a. Simultaneous neutralization of IL1α and IL1β abolished in vitro tumor sphere 
formation. Anti-IL1α (1:200) and anti-IL1β (1:200) neutralizing antibodies were added 
to medium on day 1 and day 4 after seeding Hep3B cells for in vitro tumor sphere-forming 
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assay. Data are presented as the mean number of three biological replicates ± S.E.M. See 
Fig. S7A and experimental procedures for details.  
b. IL1β and NAC co-treatment rescued the defect of NEDD4 knockdown in the in vitro 
tumor sphere formation. Control and NEDD4 knockdown Hep3B cells were treated with 
recombinant IL1β and/or NAC (0.5mM) in the in vitro tumor sphere-forming assay. Data 
were presented as the mean number of three biological replicates ± S.E.M. See Fig. S7B 
and experimental procedures for details. 
c, d. Treatment schemes and images of tumor sphere formation assay. 
e, f. NEDD4 and H3 ubiquitination are required for the maintenance of cellular ROS. 
Control and NEDD4 knockdown or H3.3 WT or K23/36/37R restored Hep3B cells were 
stained by DCFDA for cellular ROS and subjected to flow cytometry analysis. Data were 
presented as the mean DCFDA signals of three biological replicates ± S.E.M.  
g. GSH level is reduced in NEDD4 knockdown cells. Control and NEDD4 knockdown 
Hep3B cells were collected and GSH levels were measured by a colorimetric enzymatic 
reaction. Data were presented as the mean value of three biological replicates ± S.E.M. 
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Chapter 4 Discussion and Future Plans 
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Histone acetylation is generally a mark for active transcription. In eukaryote, 
glucose generally enhances H3 acetylation through the glucose downstream metabolite 
acetyl-CoA. However, it is unclear whether this metabolite-driven H3 acetylation is also 
under the control of glucose mediated cellular signaling. In this study, we uncover that 
glucose-induced H3 ubiquitination by NEDD4 specifically recruits GCN5 for H3 
acetylation, which is required for the transcription of important tumor sphere forming 
factors (Figure 23). This discovery inspired us to study which downstream metabolites 
are required for the full activation of H3 acetylation induced by glucose. Notably, our 
data suggest that not only acetyl-CoA, but also H3 ubiquitination driven by glucose 
mediated ATP production and NEDD4 activation is required for H3 acetylation, 
extending our concepts on how glucose precisely induced H3 acetylation. Although we 
found that glucose induced H3 acetylation should mainly occur in the nucleoplasm, we 
surprisingly found that glucose-induced H3 acetylation is still enriched at TSS or 
enhancers by ChIP-seq and largely correlated with glucose induced gene expression 
pattern, suggesting that glucose may just amplify the existing basal level of acetylation at 
specific loci. Based on these observations, we speculate that the global induction of H3 
acetylation by glucose shown in our western blot analysis may likely reflect the 
summation of gene/genomic locus specific decoration of histone H3 acetylation marks, 
which are first conjugated to H3 in the nucleoplasm and then deposited into chromatin at 
designated loci with the help of chromatin remodelers or histone chaperones.  
 
	 109	
	
	
Figure 23 Schematic model. 
Model of glucose-induced H3 mono-ubiquitination by NEDD4 and subsequent GCN5-
mediated H3 acetylation, which regulates tumor sphere forming and tumor engraftment 
through transcription activation of genes, such as IL1α, IL1β and GCLM. N-tail 
represents histone H3 N-terminal tail. 
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NEDD4 in many occasions is identified as a cytosolic E3 ligase, which targets its 
protein substrates mostly for ubiquitination and proteasome degradation(115). Our study 
reveals for the first time the non-proteolytic role of NEDD4 in nucleus. We show that 
NEDD4 is presented in both cytoplasm and nucleus under normal conditions. Glucose 
treatment on glucose-starved cells triggers NEDD4 Y43/585 phosphorylation for its E3 
ligase activation, providing an explanation as to why H3 ubiquitination is enhanced by 
glucose treatment. Moreover, we also identify that NEDD4 mono-ubiquitinates H3 at 
multiple sites, consistent with the capability of NEDD4 in triggering mono-ubiquitination 
on its substrates as IGF1R and IRS2(117, 145). We also found that NEDD4 did not 
display chromatin binding, which is consistent with the data indicating that glucose 
induced H3 acetylation may also occur mainly in the nucleoplasm. Although NEDD4 has 
been implicated in regulating AKT signaling(120, 121) and AKT signaling may also 
participate in the regulation of H3 acetylation(146), we did not find that AKT signaling 
is affected by NEDD4 knockdown in our glucose treatment and sphere forming 
experiments (Figure 24a and 24b). Interestingly, AKT phosphorylation is negatively 
correlated with the glucose action on H3 acetylation (Fig. S24a), which opposes the 
previous finding(146), revealing that the correlation between AKT phosphorylation and 
H3 acetylation could be altered under distinct stimuli(146). Thus, our finding showing 
NEDD4 regulates H3 acetylation and tumor sphere is unlikely through AKT signaling 
pathway. These results further extended the versatile role of NEDD4 in cellular signaling.  
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Figure 24 Akt is not involved in the glucose induced h3 acetylation by Nedd4. 
a. Hep3B cells treated with or without glucose were analyzed by Western blot.  
b. Cancer spheres from fig. 6c were analyzed by Western blot. 
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Many HATs, such as GCN5, PCAF, p300/CBP, and RTT109, are shown to 
catalyze H3 acetylation on the N-terminal tail(36, 37). Each of these HATs has its own 
preferred acetylation sites on H3. Although histone acetylation by HATs generally 
promotes transcriptional activation, it is unclear how those HATs are differentially 
utilized and how differential H3 acetylation patterns are established upon various 
stimulations. In this study, we found that under glucose stimulation conditions GCN5 
specifically acetylates K9, K14 and K27 on H3. More importantly, H3 ubiquitination by 
NEDD4 specifically recruits GCN5, but not PCAF and p300 for H3 acetylation upon 
glucose stimulation. Of note, H3 acetylation on K23 and K36, which are H3 
ubiquitination sites, are not triggered by glucose, supporting our model that these lysine 
sites are reserved for H3 ubiquitination under glucose stimulation condition to convey 
specificity for HAT recruitment. While it is thus far unclear why cells prefer to utilize 
GCN5 or its H3 acetylation sites for glucose-induced gene transcription activation, 
warranting for further explorations for HAT specificity under various stresses and/or 
stimuli, our findings collectively provide great insights into the glucose-induced histone 
acetylation.    
Tumor sphere can be formed by a subgroup of cancer cells that possesses normal 
stem cells like characteristic and likely responsible for tumor initiation, drug resistance, 
relapse and metastasis(72, 73, 97-99). These traits are generally originated from abnormal 
genetic or epigenetic alteration, including histone modification. Our study provides 
evidences that glucose-induced H3 ubiquitination as well as other components in this 
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pathway, namely NEDD4, H3.3 and GCN5, play critical roles in maintaining such 
population of cancer cells. Moreover, by ChIP-seq and microarray analysis we found that 
IL1α, IL1β and GCLM are target genes of glucose-induced H3 ubiquitination. Notably, 
we experimentally demonstrate that maintenance of tumor sphere forming cells requires 
both IL1α/IL1β and cellular ROS homeostasis. Thus in the glucose context, our results 
indicate that increased glucose demand in cancer cells is a prerequisite not only for 
producing more anti-oxidants, energy and cellular building blocks, but also for activating 
important cellular signaling to maintain H3 ubiquitination and acetylation, thereby 
driving transcription activation for crucial tumor sphere forming factors. Our findings 
further emphasize the important role of glucose in tumor sphere forming cells and provide 
a renovated view for glucose in the maintenance of tumor sphere forming cells. 
In summary, our study established a new role of glucose in transcriptome 
reprogramming, tumor sphere forming and tumor engraftment through NEDD4-
dependent H3 ubiquitination and subsequent GCN5-mediated H3 acetylation (Figure 23). 
Hence, targeting NEDD4 and GCN5 or their transcriptional targets such as IL1α, IL1β 
and GCLM may be promising approaches for cancer therapy.  
Since there are still some unsolved mysteries left in my study, I’d like to point out 
the future direction. NEDD4 deficiency affects H3 acetylation and transcription of 
selected genes, but NEDD4 does not bind to chromatin. Thus the chromatin localized H3 
ubiquitination may convey the gene specificity of NEDD4. Of note, sequential ChIP of 
ubiquitinated H3 shown its localization at the TSS of IL1A, IL1B and GCLM, indicating 
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that H3 ubiquitination may be localized at glucose target genes. However, to provide 
convincing evidence, it is better to generate specific antibody for H3 ubiquitination at 
either K23, 36 or 37 site. Using this antibody, we could perform ChIP-seq analysis to 
examine the genome wide localization of H3 ubiquitination and examine whether it is 
induced by glucose and colocalized with H3 acetylation at specific genes on chromatin. 
If this is the case, it remains to be answered that how H3 ubiquitination is deposited into 
chromatin in a gene specific manner. This might be achieved by transcription 
factor/histone chaperone coupled deposition of H3.3. To identify this mechanism, there 
might be two screening methods. First, we could use bioinformatics to search for the 
potential transcription factors that have similar binding genes with glucose induced H3 
ubiquitination and/or H3 acetylation. Secondly, we could pull down ubiquitinated H3 
using specific antibody that we generated and identify its binding proteins, which may be 
potential chaperones or transcription factors that mediate the gene specific deposition. 
Since LncRNA is reported to mediated gene specific regulation of chromatin factors, we 
should also test whether LncRNA may regulate gene specific deposition of H3 
ubiquitination and provide molecular adapters for ubiquitin recognition. Together, this 
may provide more insights into how glucose induces H3 acetylation at specific loci and 
answer the major remaining question left in my thesis project.  
Another important question is that how exactly glucose induces Nedd4 activation, 
which may be through tyrosine phosphorylation of Nedd4. Since pyruvate or ATP is not 
responsible for this, we would like to test which downstream metabolites of glucose or 
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glucose per se is important for the activation of Nedd4. There might be several 
possibilities. It has been reported that glucose elicited signaling from hexokinase when 
binding to it (147), the pathway of which is still not been identified and may convey 
kinase activity towards Nedd4. It would be also interesting to test whether glucose 
directly binds to any other proteins to activate Nedd4 E3 ligase activity, which is an 
interesting area to explore, since the direct sensing mechanism of glucose is not well 
understood in the human cells. As a well-established method in the plant biology and 
microbiology, we could screen glucose binding proteins by sepharose beads, the free 
saccharide ends of which are the immobilized glucose molecules. It is also possible that 
Nedd4 activation is mediated by the downstream metabolite of glucose that is upstream 
of pyruvate. However, those metabolites are mostly not permeable to plasma membrane, 
and could not be simply tested by treating the cells in the medium. Thus developing a 
membrane free in vitro system to test H3 acetylation is important for testing which 
metabolite is critical. In addition, since the E3 ligase activity of Nedd4 Y43/585E could 
be further enhanced by glucose, it is also possible that other mechanisms are involved in 
the glucose induced Nedd4 activation. Nedd4 is known to be activated by cellular calcium, 
which opens up the auto inhibitory formation of Nedd4. It is also implicated that glucose 
could increase calcium level in the pancreatic β-cells, thus a universal mechanism 
whether glucose increases calcium level in cancer cells should be determined and how 
glucose elevates cellular calcium level should be further identified.  
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In the future, it would be also interesting to systematically study how glucose 
induced H3 acetylation is regulated. CRISPR/Cas9 is a new technology that enabled the 
researchers to knockout genes in almost any given cell lines. The CRISPR knockout 
library covering all known human genes represents a powerful tool for functional 
screening, since its capability to suppress gene expression is many fold higher than 
traditional shRNA. By coupling FACS and next generation sequencing (NGS), we could 
first sort the cells with decreased H3 acetylation signal induced by glucose in the pooled 
library infected cells and then distinguish the enriched knockout Cas9 clones with NGS. 
Candidates from this screening would provide global information about how H3 
acetylation is regulated by the input from any other cellular signaling.  
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